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Abstract 
 During an induced immune response, the BALB/c strain of laboratory 
mouse presents ovalbumin peptides by major histocompatibility complexes that 
stimulate responding T cells. This work first investigates the nature of ovalbumin 
peptide 323-339 presentation by the Class II MHC I-Ad in an in vitro setting, then 
focuses on the engineering of an individual T cell receptor (DO11) involved in 
ovalbumin response, and finally, pursues isolation of other responding T cell 
receptors with modern high throughput sequencing techniques. 
 T cell activation requires formation of a tri-molecular complex between a 
major histocompatibility complex (MHC), peptide, and T cell receptor. In a 
common model system, the ovalbumin epitope 323-339 binds the murine class II 
MHC, I-Ad in at least three distinct registers. The DO11 T cell recognizes the 
least stable of these, as determined by peptide-MHC dissociation rates. Using 
synthesized peptides in combination with IL-2 secretion assays, we show that the 
alternate registers do not competitively inhibit display of the active register four. 
In contrast, this weak register is stabilized by the presence of n-terminal flanking 
residues active in MHC binding. DO11 is sensitive to the presence of wild type 
residues extending to at least the P-3 peptide position, and the transfer of 
flanking residues in the P-4 and P-2 positions to an I-Ad presented hen egg 
lysozyme epitope increases the activity of that epitope substantially. Further, we 
provide evidence that display of the active register is dependent on the stability of 
an adjacent, overlapping register three. When epitopes were inserted in a 
maltose binding protein carrier, activity positively correlated with stability of the 
adjacent register, which was modulated by P1 anchor residue substitutions. 
Collectively, these results illustrate the potential of flanking residue modification 
to increase the activity of weakly bound epitopes. This represents an alternative 
to substitution of anchor residues within a weakly bound register, which we show 
can significantly decrease the activity of the epitope to a T cell responder. 
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 In order to monitor the presentation of ovalbumin peptides, we have 
engineered a high affinity, multivalent single chain T cell receptor complex that 
exhibits specificity towards the OVA 323-339 peptide when displayed by I-Ad. 
DO11 was expressed as a single chain T cell receptor at levels in excess of 30 
mg/L when oriented as beta variable region followed by alpha region separated 
by a flexible linker and incorporating previously identified solubility-inducing 
mutations. High affinity variants of DO11 were obtained from a randomized 
CDR3α library displayed as pIII fusions by M13 bacteriophage and panned 
against the DO11-specific, pMHC-mimicking antibody KJ1-26. ScTCR dimers 
were created by introduction of a hexapeptide EE-epitope tag into the flexible 
(G4S)4 linker, followed by complexation with a specific monoclonal antibody. 
Tetramers were formed by further association of dimers with a fluorescently 
labeled α-IgG1, and shown to specifically target peptide-loaded lymphoma cells 
in flow cytometry.  
 The applicability of scTCR protein expression and phage display 
techniques is also explored with other TCRs and found to be generally applicable 
to those containing mouse TRBV13-2, a gene previously noted for its preferential 
usage in the responding repertoire in mouse autoimmune models. We also show 
that 172, a TCR isolated from a mouse experimental autoimmune 
encephalomyelitis model, can be expressed at high levels as a fusion with the 
short peptide IT9302, a peptide from the C-terminus of interleukin 10 shown to 
possess many of the immunosuppressive characteristics of its parent cytokine. 
 We also report on the adaptation of phage display vector pMoPac24 to 
display fusion proteins with M13 major coat protein pVIII along with three 
previously identified display-optimized variants. We find that the production of 
phage particles containing these fusions and surface display is specific to the 
variant being expressed, but we demonstrate more efficient display for pVIII 
fusions as compared to pIII for DO11, as measured by inhibition of Interleukin 2 
(IL-2) secretion during a 24-hour incubation with antigen presenting cells and 
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specific peptide. The use of these vectors may be necessary for directed 
evolution of T cell receptors exhibiting low affinity interactions with their target 
peptide/MHC complexes.  
 Finally, we report on the high throughput sequencing of mouse T cell 
receptor genes using pyrosequencing technologies. Alpha and Beta primer sets 
were designed to amplify cDNA from isolated mouse total RNA. The set was 
validated on T Cells isolated from mouse spleens, and used to identify T cell 
receptor genes from two clones, 3B6 and 4C4. A high throughput comparison of 
ovalbumin immunized mice and unimmunized controls is in progress. 
Identification of and subsequent engineering of T cell receptors involved in the 
ovalbumin response may provide further tools for future research on this murine 
system. 
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CHAPTER 1 
INTRODUCTION 
 Ovalbumin has long been employed in studies of the murine immune 
system because of its widespread availability. This work examines a very specific 
slice of protein-protein interaction arising after ovalbumin immunization within a 
much larger series of immunologic events. First examined is the interaction 
between a small fragment of ovalbumin (residues 323-339) and the protein 
displaying that antigen, class II major histocompatibility complex (MHC) I-Ad on 
specialized antigen presenting cells (APCs). Next, the DO11 TCR responding to 
that specific pMHC is engineered for production in soluble form and for binding to 
its target with higher affinity. Finally, methods for high throughput sequencing of 
the ovalbumin-responsive TCR repertoire are reported, such that other TCR 
candidates for engineering might be identified, and that the data might give us 
greater understanding of the larger immune response. To place these pursuits in 
their proper context, a brief overview of the T cells function within the immune 
system will initially be presented, followed by an examination of selected 
developments in recombinant protein that are specifically applied here to TCRs. 
1.1. T Cells in the Adaptive Immune System 
 T cells comprise one branch of the body’s adaptive immune system. The 
immune system consists of “lymphatic” tissues and vessels that provide access 
for its components to monitor and combat disease. The innate immune response 
consists of a variety of cells and proteins adept at identifying pathogens through 
common motifs, mobilizing effectors, and stimulating adaptive immune 
responses.  
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 The adaptive immune system is the body’s specialized defense system 
against the rapidly evolving world of disease-causing agents. When properly 
stimulated, it can specifically recognize and eliminate a broad spectrum of 
viruses and cancerous cells. The system is replete with checks and balances that 
mediate its aggression. Improper stimulation can cause diseased cells to be 
ignored (e.g. latent tuberculosis or HIV) or healthy tissues to be attacked 
(autoimmunity). Much of the potency of the adaptive immune system lies in the 
range of T cells and B cells functions. Adaptive responses are antigen-specific: T 
cells and B cells possess tremendous diversity in their receptors, which allows 
them to carry out a tailored defense against viral or bacterial threats. In addition, 
T cells play integral roles in responses unrelated to specific pathogens, as in 
autoimmunity, cancer, and transplant rejection. T cells act through the 
recognition of peptides (protein fragments) displayed on cell surface major 
histocompatibility complexes. Based on the nature of TCR interactions with 
peptide/MHC (pMHC), and the environment in which it is received, the cell may 
receive a variety of distinct signals that in turn, coordinate other aspects of 
immune response (Figure 1.1). 
 
Figure 1.1. T Cell Interaction with an Antigen-Presenting Cell.  
T Cells recognize peptides in complex with MHC on the surface of antigen-presenting 
cells. Activation is dependent on peptide recognition as well as the interaction of 
costimulatory receptors. Cellular interaction is stabilized by adhesion proteins. (Source: 
(1)) 
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 The majority of the T cell repertoire is composed of two different types: 
CD8+, or cytotoxic T cells, and CD4+, or helper T cells. CD8 and CD4 themselves 
are co-receptors, surface molecules that are thought to facilitate the interaction of 
T cell receptors by binding to constant regions of an MHC and stimulate 
intracellular signaling pathways. CD8+ T cells specifically bind to MHC Class I, 
and CD4+ T cells to MHC Class II. Activated CD8+ cells generally respond with a 
cytotoxic barrage. They release cytokines and granzymes that destroy the target 
cell. CD4+ cells, on the other hand, orchestrate an effector response that is 
carried out by other cells, such as macrophages and B cells. Within CD4+ and 
CD8+ T cells are subtypes with distinct behavioral patterns. More detail on these 
types and the criteria for activation of T cells is presented below. In order to 
understand the distinct functions of CD4+ and CD8+T cells, the role of the MHC in 
antigen processing must be understood. 
 
Figure 1.2. Coreceptors Facilitate T Cell Binding.  
CD4 and CD8 Proteins interact with non-polymorphic regions of MHC during T cell antigen 
recognition. (Source: (2)) 
1.1.1. Antigen Presentation 
 Major histocompatibility complexes are glycoproteins classified as either 
class I or class II. MHC class I display peptides from within a given cell in a 
binding pocket composed of a single protein. Virtually all cells (including 
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professional antigen-presenting cells) express MHC I. As proteins are 
synthesized within cells a fraction are degraded; the resulting peptide fragments 
are complexed with MHC I molecules in the endoplasmic reticulum. These 
complexes migrate to the cell membrane, where they may interact with scanning 
CD8+ T cells. MHC class I thus present a cross-section of the proteins produced 
inside a given cell, including foreign proteins present in an infected cell. Class II 
MHCs are heterodimers, whose binding pockets are made up of two distinct 
proteins. Unlike class I, class II MHCs are presented only by specialized antigen-
presenting cells: macrophages, dendritic cells, and B cells. These cells 
internalize and degrade extracellular material, displaying the resulting peptide 
fragments and exhibiting any proteins that may be present in infected or inflamed 
tissue. MHC I and II also differ in the lengths of displayed peptides. The MHC I 
peptide binding pocket is closed, and displays peptides of only 8-10 amino acid 
residues in length. MHC II pockets are open ended, allowing long peptide 
fragments to overhang. There is theoretically no limit to the size of peptide that 
may be displayed by class II MHC. In practice, overly long peptides are trimmed, 
and the complex typically displays peptides made up of 13-17 amino acids (3). 
 
Figure 1.3. MHC Structure.  
MHC Class I (Left) and Class II (Right) are membrane bound proteins that display peptide 
fragments in their outermost domains (α1 and α2 for MHC I, α1 and β1 for MHC II).  
(Source: (1)) 
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 The ability of an MHC to display a peptide “epitope” is dependent on non-
covalent amino acid contacts between the peptide and its pocket-like binding 
site. MHCs are polygenic and polymorphic, meaning that several different genes 
code for MHCs, and many variations of these genes exist. All told, heterozygous 
humans can possess six different MHC alleles, (two each of HLA-DR, -DQ, and –
DP) and mice four (two each of I-E and I-A). This genetic variety increases the 
landscape of peptides represented in MHC display (for review: (4)). 
1.1.2. T Cell Development 
 T cells originate in the bone marrow as undifferentiated stem cells. Some 
of these cells migrate to the thymus, a lymphatic organ in the chest cavity, where 
they are differentiated toward a T cell lineage in the thymic stroma. In the 
thymus, the cells undergo genetic rearrangement to form functional T cell 
receptors in a process known as VDJ recombination. Each T cell receptor is a 
heterodimer consisting of an “α” and “β" chain (Figure1.4). Gene segments in 
each individual T cell rearrange to create a single gene for each chain, which, 
after transcription, combine to form a unique receptor (Figure 1.5). Each chain 
consists of a variable and constant (or germline) region. Variable regions are 
located at the interface of variable (V), diversity (D), and joining (J) gene 
segments for β chains (α chains contain no “D” segments). Additional diversity in 
TCRs is achieved through the incorporation of random nucleotides during gene 
rearrangement, known as p- and n-nucleotide addition. The total theoretical 
diversity of human T cells is estimated at approximately 1018 unique TCRs (3). 
The recognition of peptide/MHC takes place largely through three loops present 
on both chains that contact the binding partner. These loops are known as 
complementarity-determining regions (CDRs). More detail on antigen-recognition 
is discussed below.  
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Figure 1.4. T Cell Receptor Structure.  
Each TCR chain consists of a constant and variable region (Left). Disulfide bonds in the 
variable region expose 3 loops (right, in red), known as complementarity-determining 
regions, to peptide/MHC for recognition.  (Source: (1)) 
 
Figure 1.5. VDJ Recombination.  
Diversity in T cell receptors is created through the random, but stepwise pairing of V-D- 
and J gene segments. (Source: (5)) 
 T cells are functionally selected in the thymic stroma through the 
processes of positive and negative selection. In order survive, developing cells 
must recognize peptides in the thymus, but not interact too strongly. In the 
thymus, about fifty million thymocytes are generated each day, with only 2-4% 
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continuing on to the body as mature T cells. T cell progenitors in the thymus 
require stimulation to survive, but thymic stromal cells present only native, or 
“self” peptides to these thymocytes (Figure 1.6). Most developing T cells cannot 
recognize self-peptide/MHC, and thus do not receive the stimulation necessary 
for survival. These cells continue to rearrange their receptor genes until a 
“functional” TCR is produced, or die idly. This process, known as positive 
selection, orients the T cell repertoire to recognize an individual’s personal set of 
MHC alleles. An estimated 10-30% of rearranged T cells bind successfully to 
self-peptide/MHC, and are positively selected (3). 
 
Figure 1.6. Developing T cells in the Thymus.  
T cells encounter self-antigen presented by cortical epithelial cells and antigen presenting 
cells during maturation in the thymus.  (Source: (6)) 
 In order to survive, however, cells must also avoid negative selection, the 
process that removes self-reactive T cells. In addition to thymic stromal cells, 
developing T cells encounter antigen-presenting cells (APCs) that originate in the 
bone marrow. Apoptosis (programmed cell death) is induced in T cells that 
strongly interact with these cells. Strong self-reactivity in mature T cells could 
predispose an individual to an autoimmune response.   
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 The mechanisms by which positive and negative selection occur are not 
completely delineated. The different cell responses, i.e. stimulation or apoptosis, 
are thought to be a function of signals propagated by the T cell receptor, and are 
almost certainly also a function of secondary signals in the thymus. In addition to 
positive and negative selection, some developing T cells will become regulatory 
T cells, which will be discussed below.  
 Thymic education of T cells ensures that the peripheral repertoire will 
largely be able to distinguish self from non-self, despite having been exposed 
essentially only to thymic tissue. Two distinct characteristics enable this efficient 
education. Typically, gene regulation is very tissue- and developmentally- 
specific. A given human cell expresses a limited number of proteins based on the 
function of its particular cell type. However, thymic stromal cells exhibit 
indiscriminate gene expression. A transcriptional regulator known as autoimmune 
regulator (AIRE) controls the expression of genes common to various cell types 
and ensures comprehensive expression of genes from these tissues. The other 
contributing factor to efficient thymic education is its architecture. Cells are 
closely grouped, forcing a developing cell to come into contact with many self-
peptide/MHC. A developing cell spends an average of a week in the process of 
thymic education. The entirety of the process of weeding out self-reactive cells in 
the thymus is known as central tolerance. Despite its efficiency, self-reactive cells 
invariably remain, left to be controlled by peripheral tolerance mechanisms, as 
discussed below (7). First, consideration is given to how T cells are activated. 
1.1.3. T Cell Activation 
 Following thymic development, mature T cells enter circulation. The 
“periphery” of the lymphatic system is defined as all lymph nodes and vessels 
outside of the thymus and bone marrow. T cells that mature in the thymus exit to 
the periphery, where they circulate via blood and lymphatic vessels between 
various lymph nodes. Peripheral cells require stimulation to survive, in a process 
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similar to that of positive selection in the thymus. In the absence of sustaining 
stimulation or activation by cognate antigen, the cell will die. Turnover of one to 
two million cells a day is common (3). 
 Activation of T cells occurs in lymphoid tissues and is dependent on the 
recognition of cognate antigen and costimulatory signals. Dendritic cells, B cells, 
and macrophages ingest extracellular antigen, process intracellular peptides and 
display them on surface MHC. Stimulated antigen presenting cells stop ingesting 
extracellular materials, start displaying large amounts of peptides, and migrate 
from inflamed sites to lymphoid tissues. Activated APCs also display B7 
molecules, which are responsible for the costimulation of T cells. When naïve T 
cells recognize antigen via the TCR and B7 costimulatory signal via CD28, they 
begin to produce large amounts of growth factor IL-2, and divide rapidly into 
effector cells. In the absence of costimulation, as in signaling through 
unstimulated APCs or peripheral cells, T cells become anergic (discussed 
below). Activated T cell clones, in contrast, often no longer require costimulation 
to carry out effector functions (3). 
 Upon activation and clonal expansion, armed effector T cells respond 
based on their cell type. Activated CD4+ T cells stimulate immune response 
through the release of cytokines, and the activation of effectors such as 
macrophages and B-cells. Upon stimulation, helper T cells differentiate into Th1 
or Th2 cells, which shift immune response towards being cell-based, or humoral-
based, respectively (Figure1.7). Differentiation is based on characteristics of the 
pathogen and the stimulating APC. 
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Figure 1.7. Stimulated CD4+ T cells Adopt a Th1 or Th2 Type.  
Upon encounter with antigen, antigen presenting cells produce a variety of cytokines that 
signal responding T cells to coordinate a Th1 (inflammatory) or Th2 (humoral response).   
(Sourece: (1) ) 
 An inflammatory environment and the presence of activated macrophages 
and IgG characterize cell-based immunity (Figure 1.8, left). Th1 cells release 
inflammatory cytokines such as IFN-gamma and TNF-α that drive this response. 
Humoral responses are characterized largely by the presence of antibodies, 
mainly IgM, IgA, and IgE, as well as anti-inflammatory cytokines secreted by Th2 
such as IL-4, IL-10, and TGF-β (Figure 1.8, right). Inflammatory responses are 
typically associated with viral infections and autoimmunity, whereas humoral 
responses are associated with extracellular bacteria and allergy. The class of 
immune response generated can significantly affect the course of a particular 
disease. The impact of multiple sclerosis is thought to be mitigated by a shift from 
inflammatory to humoral response (8). Patient survival against mycobacterium 
leprae, on the other hand, correlates to an inflammatory Th1 response (9). In 
addition, environments are self-regulating, in that cytokines produced by Th1 
suppress Th2 cells, and vice versa. 
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Figure 1.8. Inflammatory vs. Humoral Immune Response.  
Inflammatory immune response is driven primarily by Th1 activation of macrophages that 
have been infected or have ingested antigen. Humoral response is driven by Th2 
activation of B Cells and is characterized by the secretion of cytokines that stimulate B 
cell growth. (Source: (3)) 
 In contrast to the mostly indirect response of helper T cells, CD8+ T cells 
are directly cytotoxic to infected cells in the periphery. In turn, CD8 cells have a 
higher threshold for activation. This threshold can be met through activation by 
mature dendritic cells, or through help granted by the presence of CD4+ T cells.  
Cytotoxic effector molecules such as perforin and granzymes induce target cell 
lysis. CD8+ T cells also display surface expressed Fas ligand, which can induce 
apoptosis in target cells. 
1.1.4. Tolerance 
 Unrestricted activation of peripheral T cells would be destructive to the 
host, as self-reactive T cells invariably circulate. The process of thymic education 
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is not complete, and some self-reactive T cells escape deletion. In addition, many 
foreign antigens pose no threat, and the host is best served by ignoring them.  
Tolerance is the means by which the host avoids potentially harmful T cells 
responses; it can be induced in lymphoid or non-lymphoid tissues. Significant 
among the former are tissues that encounter a huge variety of foreign antigens 
as in the gut-associated lymphoid tissues. The mechanisms of tolerance 
induction are of significant interest in the study of autoimmunity. 
  Tolerance can be sub-classified into peripheral and central tolerance.  
Central tolerance refers to the thymus, and includes the previously described 
mechanism of thymic education as well as T regulatory cells that originate in the 
thymus. Peripheral tolerance refers to any tolerance independent of the thymus, 
including clonal deletion, anergy, and peripherally derived T regulatory cells.   
1.1.4.1. Anergy and Clonal Deletion 
 Lymphocytes are said to be anergic when they become functionally 
inactivated after encountering an antigen, yet remain alive and resistant to 
activation. Clonal deletion, on the other hand, occurs when T cells die upon 
antigen encounter. Generally, naïve T cells that recognize antigens (foreign or 
self) in the absence of costimulation become anergic or are deleted. Necessary 
costimulatory signals are provided by the innate immune system, which depends 
on inflammation produced by motif recognition or tissue injury. The decision to 
become anergic or die probably depends on the nature of the TCR interaction as 
well as tissue-specific factors and levels of antigen-presentation (for review: 
(10)).  
1.1.4.2. Regulatory T Cells 
 Regulatory T cells were initially thought to be a sub-population of anergic 
T cells that acquired the capability to induce anergy in surrounding cells (11).  It 
has since become clear that regulatory T cells are neither strictly anergic, nor 
strictly generated in the periphery (12). However, the capability to subdue an 
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active immune response has made these cells an inordinately well-studied cell 
population and attractive target for immunotherapy. Various groups have 
presented evidence for seemingly distinct classes: Tr1 and Th3, which are 
generated in the periphery, and natural T regs, CD4+Foxp3+, which primarily 
originate in the thymus. The latter are the most well characterized group. 
 Natural T regulatory cells are helper (CD4) cells that have historically been 
marked by the presence of CD25. However, not all CD25+ cells are regulatory, as 
this surface molecule is a receptor for growth factor IL-2 and is expressed on 
activated T cells. The most reliable indicator of this regulatory class of T cells is 
the expression of the Foxp3 transcription factor. This factor is thought to mediate 
a wide variety of cellular processes and is essential to the development of T 
regulatory cells.  
 Many, probably most, CD4+Foxp3+ T regs develop in the thymus as self-
reactive T cells that have escaped deletion. Mice subject to a thymectomy prior 
to day 3 of life (when T regs first leave the thymus) develop autoimmune 
disorders (13). Natural T regs exert dominant immunosuppression in the 
presence of CD25- cells, which has made them an attractive population for 
immunotherapy (12, 14-16). The mechanism by which T reg cells act is as yet 
unclear, as divergent results have emerged in vitro and in vivo. In short, their 
mechanisms seem to be wide-ranging, and include direct interaction with 
responding T cells and indirect suppression mediated by interaction with antigen 
presenting cells. Immunosuppressive cytokines IL-10 and TGF-β play a role, as 
well as competition for binding with the IL-2 stimulatory cytokine, and expression 
of the CTLA-4 receptor, an inhibitory receptor for B7 costimulatory receptors. The 
development of T regs is influenced by high affinity TCR interactions with self-
peptide (17-20). 
1.1.5. Molecular Mechanisms of T cell activation  
 The interaction of T cell receptors with pMHC occurs through molecular 
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contacts in its six CDR loops (three per variable region). The TCR docks 
diagonally with the MHC such that the alpha chain loops are oriented towards the 
N-terminus of the peptide, and the beta chain towards the C-terminus. The 
peptide lies in a groove between parallel alpha helices of the MHC, and makes 
specific contacts with both CDR3 loops. Of the nine peptide residues within this 
binding pocket, typically at least three side chains are significantly solvent 
exposed, and are capable of forming specific van der Waals contacts and 
hydrogen bonds with TCR (for review, (21)).  
 TCR contacts with the MHC itself occur through interaction of CDRs 1 and 
2; TCRβ regions interaction MHCα1 helix, and TCRα regions interact with the 
MHCβ2 helix (or MHCα2 in the case of class I complexes). Within this conserved 
arrangement, however, these germline-encoded TCR regions seem to possess 
remarkable polyspecificity (22). Variable gene usage does not seem to be 
restricted for particular MHC genes, and a single variable region may adopt 
different crystal contacts in its CDR1 and CDR2 depending upon the binding of 
the flexible CDR3 loop to the peptide.  
 This flexibility in recognition seems integral to the actions of T cells in the 
periphery. Recognition is hypothesized to occur by a two-step mechanism: CDRs 
1 and 2 transiently binding the MHC and allowing the flexible CDR3s to alter 
conformation, forming specific peptide contacts (23). This mechanism would 
allow for T cells to “scan” presented peptides. There is evidence that continued 
recognition of the more prevalently presented self peptide-MHC complexes 
delivers a positive signal below the activation threshold that is required for 
survival of peripheral T cells. 
 Various models have been proposed to explain T cell activation based on 
a small number presented foreign peptides in the midst of many self-peptides. 
The serial triggering model suggests that each specific pMHC activates a number 
of specific TCRs (24). This predicts that an optimal strength of TCR-pMHC 
interaction exists, beyond which T cells are insufficiently activated. The kinetic 
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proofreading model emphasizes that a complex half-life of a certain duration is 
necessary for cooperative binding events necessary for signaling in T cell 
activation (25). Molecularly, there is considerable evidence that TCR signaling, 
mediated by the CD3 complex, involves the aggregation of various TCRs and 
their coreceptors and changes in localization of the cell surface surrounding the 
site of engagement (26). 
1.2. Protein Engineering  
 Antibodies and T cell receptors (TCR) are the two principal targeting 
entities of the adaptive immune system, endowed with specific antigen 
recognition capabilities. Antibodies have found favor in the pharmaceutical 
industry, and along with that, extensive engineering platforms have been 
developed that have been drawn from in work with TCRs. 
1.2.1. Monoclonal Antibodies 
 While the structural and genetic similarities of antibodies and T cell 
receptors are extensive, key differences include the ability of antibodies to 
recognize virtually any three-dimensional molecule (small molecule, lipid, 
carbohydrate, protein) with high affinity. TCRs, on the other hand, are exclusively 
membrane-bound, recognizing target peptides processed and presented by other 
cells with low affinity. Both possess substantial diversity due to gene 
rearrangement through VDJ recombination; receptors are formed through the 
recombination of disparate gene segments in the host cell’s DNA. Unlike TCRs, 
antibodies undergo further rearrangement in the periphery in a process known as 
somatic hypermutation. By this process, individual nucleotides in the genes are 
randomly changed, followed by selection for high affinity variants (3). Antibodies 
are prominently used in diagnostics and therapeutics. As of 2008, 21 antibodies 
had been FDA approved as therapeutics, with over 400 others in clinical trials 
(27).  
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 Antibodies are composed of two identical subunits assembled more or 
less in a “Y” conformation (Figure 1.9), with each branch capable of recognizing 
a target antigen. Each subunit is composed of a light and heavy chain, which are 
further subdivided into constant and variable regions. Variable regions are 
responsible for antigen recognition, while constant regions bind to other immune 
system effectors. As with the TCR, each variable region presents three solvent-
exposed loops (complementarity-determining regions 1-3, CDR1-3) that contact 
the antigen, and define the specificity of the molecule. 
 
 
Figure 1.9. Antibody Structure.  
(Source: (1)) 
 Specific antibodies may be isolated in several ways. The classical method 
involves the creation of hybridomas. By this method, B cells are harvested from 
mice immunized with a particular antigen (28). These responding cells are fused 
with immortalized tumor cells; the resulting hybridomas retain the ability to 
produce antibodies as well as the immortal characteristics of the fusion partner. 
From a pool of hybridomas, specific cells are selected secreting genetically 
identical monoclonal antibodies (mAbs). These are likely to possess high affinity 
and specificity, as they have been subject to the physiological refining process of 
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somatic hypermutation. Because they are derived from a mouse, mAbs are 
highly immunogenic when used therapeutically in humans. Immunizing humans 
for antibodies is in many cases unethical and has the potential to induce harmful 
side effects, as in immunization with self-antigens. However, antibodies against 
self-antigens are often desirable, for instance, as targeting agents for cancerous 
cells. These concerns have led to the development of strategies to minimize 
immunogenicity while retaining the advantages of hybridoma technology, namely 
chimerization and humanization of murine antibodies. 
 Chimerization involves appending murine variable regions to human 
constant regions (29). Alternatively, antibodies may be humanized by grafting 
only the mouse CDRs onto a human antibody “scaffold” (30). To retain their 
potency, however, scaffolds generally must be modified so that displayed loops 
retain their native conformations. 
 As an alternative, murine involvement may be bypassed altogether 
through the use of naïve and synthetic libraries (31). Naïve libraries are 
harvested from the blood or other peripheral immune locations of humans who 
have not been immunized against a particular antigen. Because they lack 
somatic hypermutation, antibodies isolated from these libraries are typically of 
lower affinity.   
 Synthetic libraries take advantage of developments in scaffolding 
templates and phage display to provide large, specific libraries. Typically, 
synthetic libraries are created by fusing fully randomized complementary-
determining loops to stable scaffolds. In the Human Combinatorial Antibody 
Library Project (HuCAL), a stable scaffold was creating using consensus 
framework regions, with randomized CDR3 introduced with oligonucleotides (32). 
Many antibody variants with high affinity and selectivity for chosen ligands have 
been selected from this library. Well-designed synthetic libraries can produce 
high affinity molecules, including antibodies against self-antigens, which are 
deleted in physiological settings. 
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Naïve and synthetic libraries are frequently combined with phage display 
technology to identify lead variants and then improve their affinity for ligand. This 
process is discussed further in section 1.2.3 and chapter 3. 
1.2.2. TCR-like Antibodies 
 Limitations in the TCR repertoire have led to attempts to develop 
antibodies that recognize specific peptide/MHC complexes (for review (33)). 
Antibodies are naturally of higher affinity, in part because the previously 
discussed processes of thymic education that limits TCR affinity, as well as the 
lack of somatic hypermutation in TCRs. In addition, antibodies are naturally 
produced in a soluble, stable conformation, whereas the development of soluble 
versions of normally membrane-bound TCRs has been slower. However, the 
development of peptide-specific antibodies has proven difficult as well, as early 
reports indicated these were primarily reactive with the MHC (34-37).  
 Unlike antibodies, TCRs are genetically encoded to discriminate 
specifically for a specific peptide in the context of an MHC. Given the difficulty in 
isolating pMHC-specific Abs, it has been suggested that antibodies are, in 
contrast to TCRs, genetically predisposed to ignore peptide/MHC, as no peptide 
antigens are present to provoke negative selection physiologically, and 
recognition could result in an autoimmune reaction against antigen presenting 
cells (38). Indeed, TCR-like antibodies isolated from large naïve libraries have 
been reported as having greater peptide specificity (39-42). Even in the absence 
of strong genetic predisposition against selection, the small surface area of 
exposed peptide (~25% of total pMHC binding site) represents a daunting target 
for libraries of variants capable of recognizing any three-dimensional structure. 
 Two crystal structures for TCR-like antibodies have been reported. Hyb3, 
specific for a tumor-associated melanoma antigen, was shown to bind in a 
distinctly MHC-specific manner, with only four of its six CDRs active in binding 
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(43). In contrast, the 25-D1.16 antibody specific for an ova peptide bound to 
class I H-2Kb adopts a canonical binding mode seen in TCRs (44). 
  The future utility of TCR-like antibodies as compared to TCRs themselves 
will depend on the ability of each platform to overcome its own hurdles: TCRs in 
producing soluble, high affinity reagents, and TCR-like antibodies in reliably 
targeting specific peptides. 
1.2.3. Directed Evolution 
 Directed evolution is the process by which a protein is modified for a 
desired characteristic. It involves the generation of a mutant library, packaging 
into a host for display, and selection based on biochemical or biophysical 
properties of interest. Reported applications include the mapping of epitopes 
involved the interaction of specific proteins (45-47), generation of novel protein 
function (48, 49), optimization of metabolic pathways through modification of 
promoter or transcription factors (50, 51) and enzyme engineering, such as 
modulation of substrate use (52) or generation of novel catalytic activity (53). The 
basis for any selection mechanism is the connection between DNA and protein, 
such that genetic variants responsible for phenotypic change may be predictably 
isolated. This is most commonly accomplished by fusing the protein of interest to 
a naturally displayed host protein. Selection is typically accomplished through 
several successive rounds of sorting and amplification (Figure 1.10). 
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Figure 1.10. Phage Panning. 
 In this work, a T cell receptor is selected for increased affinity by means of 
bacteriophage display. Phage and their bacterial hosts are robust, with selection 
and subsequent recovery procedures simple and reliable. In addition, phage 
routinely encapsulate libraries in excess of 1010 unique variants (54). Various 
alternatives exist. Anchored periplasmic expression (APex (55)) also utilizes a 
bacterial host, but fused proteins are immobilized along the inner membrane, and 
require outer membrane disruption for exposure. Variants are selected by 
fluorescent sorting with a tagged ligand, and recovered via PCR amplification. In 
yeast display, eukaryotic yeast are used as an expression host, which facilitates 
the screening of more complex proteins requiring post-translational modifications 
(56). As with APex, variants are often sorted using flow cytometry, yet PCR is not 
necessary for identifying selected mutants, as intact yeast can be propagated 
post-selection. Typical library sizes associated with yeast display are between 
105 and 107 mutants (57), as transformation of a library into yeast is generally 
less efficient than bacteria.  
 As an alternative to fusion proteins, ribosomal display takes advantage of 
the observation that in the absence of termination during translation, a free 
ribosome maintains the association of a nascent protein with its respective 
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mRNA (58). This process utilizes an in vitro transcription and translation system 
to avoid the use of a host, which often limits the diversity of the library (59). Only 
the number of ribosomes present restricts the diversity of ribosomal display. 
However, mRNA is very unstable compared to DNA, and nascent protein is 
necessarily connected with the bulky translation machinery during selection (60). 
1.2.3.1. M13 Bacteriophage 
 Bacteriophages are viruses that infect bacterial cells. They are estimated 
to be the most abundant form of “life” on earth, with on the order of 108 found per 
milliliter of ocean water (61). One particular form, the M13 filamentous 
bacteriophage has been co-opted for the purposes of protein engineering (62). 
M13 is a non-lytic phage that has proven adept at displaying proteins ranging in 
size from small peptides to large immunoglobulins. Phage display is predicated 
on the physical connection genotype and phenotype in simple packaging. This 
allows for desirable DNA variants to be functionally selected and amplified. M13 
particles are slender and long; they are made up of six different coat proteins that 
encapsulate single stranded DNA (Figure 1.11). The length of the particle ranges 
from approximately 700 nm to 2000 nm, with a diameter of only 6-7 nm. Protein 
VIII (pVIII) composes a majority of the particle, with thousands of copies 
encapsulating the drawn-out single stranded plasmid. At one end of the particle, 
approximately five copies of protein VI dangle off the end along with three to five 
copies of protein III (pIII), which mediates infectivity of the particle. At the other 
end five copies of proteins VII and IX reside, bound to the packaging signal on 
the encapsulated plasmid. 
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Figure 1.11. M13 Filamentous Bacteriophage. 
Phage particles allow for elements of a DNA library to be functionally selected. DNA in the 
form of phagemid is stored within protein VIII coat; the gene coded for is displayed as a 
fusion with protein III.  Other phage proteins may also be utilized in display. (Source: (63)) 
 Phage particles infect bacteria via interaction with the bacterial F-pilus, a 
protein tube required for transfer of the F plasmid between adjacent cells. As the 
phage penetrates from the exterior of the cell through the bacterial and 
cytoplasmic membranes, its DNA is released from coat proteins, which migrate 
and become part of newly formed phage particles. The complement to the “plus-
strand” phage-encapsulated DNA is then synthesized by bacterial replication 
machinery. This newly formed “negative“ strand serves as the template for phage 
RNA production, which is then transcribed to produce viral proteins. Proteins II 
and X assist in replication of the viral DNA strand. Protein V interacts with the 
newly synthesized single stranded DNA, creating the drawn out structure that is 
incorporated in new phage particles. 
 Synthesized coat proteins migrate through the cytoplasmic membrane via 
the “sec” pathway to engage in particle assembly at the inner membrane.  
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Assembly is thought to be initiated by a “packaging signal” in the single-stranded 
DNA which binds to inner membrane-bound protein VII and protein IX. The DNA 
is then extruded through the membrane, with positively charged pVIII molecules 
interacting with the DNA to form the coat during transport. Assembly is 
completed when the DNA sequence ends, and proteins III and VI come into 
contact with this end of the DNA. In the absence of protein III to terminate 
assembly, the particle may take up another copy of the DNA and continue 
synthesis (64). 
 The M13KO7 phage used in this work contains a selectable kanamycin 
resistance gene as well as a modified packaging signal. Although it is capable of 
replication, a plasmid containing the wild-type origin of replication (phagemid) will 
be preferentially packaged into produced particles. Phagemid contain both phage 
and bacterial origins of replication, and can thus be subjected to modification by 
typical molecular biological techniques prior to their use in phage. The phagemid 
used in this work code for only a single bacterial protein. In order to package 
them into phage particles, helper M13KO7 phage must be added, which then 
synthesize the remainder of the proteins necessary for particle formation. 
 In this work, phagemid fuse proteins to copies of pIII or pVIII. For pIII, the 
gene is fused to a c-terminal fragment of the gene, such that it is incorporated 
into the surface of the phage particle in similar fashion to other copies of the 
protein III (65). This truncated version is devoid of infective properties, but due to 
its abundance, this is typically of little consequence. The presence of the protein 
is typically limited to a single copy among the three or four wild type pIII. In many 
cases, phage do not incorporate a pIII fusion at all, with some estimates placing 
this number at 90% or greater (66). Nonetheless, with M13 titers often exceeding 
1011 per mL of bacterial culture, phage particles can easily accommodate large 
diversity libraries. pVIII display is discussed further in Chapter 3. 
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1.2.3.2. Library Creation 
 The introduction of genetic variation for selection can be carried out in 
random or site directed fashion, depending on the nature of the selection. For the 
alteration of well-defined binding sites, as is described in this work, a targeted 
approach is preferable. In the improvement of stability or expression levels, on 
the other hand, the targets are unpredictable, and a random approach may be 
more effective. 
 Random techniques include error-prone PCR and DNA shuffling. Error-
prone PCR is a technique that modifies the standard polymerase chain reaction 
such that errors are purposefully introduced during the replication process (67). 
PCR depends on proper binding of complementary DNA sequences during 
thermocycling and the ability of the enzyme to properly replicate template DNA 
strands. The use of a polymerase that does not proofread, high repetitions of 
thermal cycles, or unequal ratios of the four component nucleotides ensure that a 
desired error rate is maintained in amplification. In addition, low annealing 
temperatures and high concentrations of magnesium ions facilitate annealing of 
DNA sequences that are not completely complementary. Error rate is dictated by 
the specified conditions; typically a mutation rate of between 0.1 to 2% of codons 
is desirable. 
 The use of error-prone PCR is limited to smaller genes. Multiple rounds of 
mutation and selection with error-prone PCR can lead to a buildup of total 
mutations, most of which are detrimental or non-functional. As these undesirable 
errors accumulate along with the beneficial ones, functional improvement of the 
protein becomes increasingly rare. For this reason, it is desirable to select only 
for functional mutants while weeding out neutral and negative mutants. Several 
techniques, most prominently DNA shuffling and StEP recombination, seek to 
create a combinatorial pool of variants and avoid buildup of deleterious 
mutations.  
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 In DNA shuffling, a gene is broken up and recombined (68) through the 
use of DNaseI, a nuclease that digests DNA at random. The extent to which 
digestion occurs with this enzyme depends on the length of exposure. After a 
period of digestion, fragments are reassembled through a PCR reaction in which 
the fragments anneal to one another, and longer fragments that result are 
amplified by flanking primers. DNA shuffling is often performed starting from a 
pool of alleles, in attempts of preserving the useful mutants from each variant, 
though mutants generated from error-prone PCR may also be used. A single 
unmodified gene can also be used as a starting point, as the recombination 
process introduces a low level of point mutations (link). 
 Staggered extension process (StEP) recombination is an alternative to 
DNA shuffling that produces a combinatorial mixture without the use of a 
nuclease (69). The process involves replicating DNA as in PCR, except that 
abbreviated thermocycles are used such that a full-length sequence is achieved 
only after many cycles. During each cycle, fragments are extended slightly before 
being denatured and reannealed to a separate DNA template. A full-length gene 
is thus created from bits and pieces of multiple DNA templates. Unlike DNA 
shuffling, StEP requires an initial pool of variants to be used as template. 
 An alternative to the random error-based diversity creation is the 
introduction of targeted mutations with oligonucleotides (70). Short 
oligonucleotides bind to DNA and are incorporated in a newly created strand 
during PCR amplification. Oligos containing mutations sandwiched between 
strictly complementary flanking regions can introduce mutations into the target 
DNA. Moreover, a collection of oligos coding for all different amino acid 
sequences can introduce “random” mutations at a defined number of amino acid 
positions. Multiple oligos may be used to randomize disparate positions on a 
gene. 
  A single round of oligonucleotide amplification has the potential to 
completely randomize a series of amino acids. Randomized codons may be 
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indiscriminate (NNN) or designed to enrich for specific classes of amino acids 
based on patterns in the genetic code. A complete NNS codon, for example, 
codes for all twenty amino acids, but includes two fewer stop codons than a fully 
randomized NNN. Other codons exist for substituting groups of similar amino 
acids such as hydrophobic or hydrophilic residues (71). 
 Site-directed oligos can be used to amplify an entire plasmid linearly using 
a single oligo and single-strand DNA template, or exponentially, with double-
stranded template and two opposite sense primers. Alternatively, oligos can be 
amplified using an overlap PCR strategy within a larger cassette that is later 
digested and ligated into the plasmid. Full plasmid amplification is preferable, as 
digestion and subsequent ligation are poorly efficient and can reduce the size of 
the resulting library. For this reason, even random methods have been adapted 
to full plasmid amplification, using cassettes up to 1 kb containing randomly 
distributed mutations as “mega-oligos” to amplify around the plasmid (Pai, in 
submission). Following full plasmid amplification, covalently closed-circular, 
double-stranded DNA (CCC-dsDNA) containing mismatched regions are be 
transformed into E. coli, which amplifies each strand individually. Pre-treatment 
strategies for the template DNA reduce the presence of the wild type after 
amplification. The template may be methylated, and treated with the CpG specific 
restriction enzyme DpnI after amplification. Alternatively, the template DNA can 
be grown in the presence of uridine in a strain deficient in thymine incorporation 
(dut-,ung-), and later transformed into a strain that preferentially inactivates 
uracil-containing dna (ung+). 
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Figure 1.12. Oligonucleotide Based Mutagenesis. 
Mutant oligos bind to DNA flanking CDR3α , the CDR itself containing randomized NNS 
codons. An enzymatic reaction creates a copy of the phagemid incorporating the oligo. 
Upon transformation into E. coli, the wild-type DNA with dUTP will be preferentially 
degraded; surviving colonies will comprise the library. (Adapted from: (54)).  
 In this work, library creation is performed according to the protocol of 
Sidhu and Weiss (Figure1.12, (72)). Oligos containing randomized NNS codons 
are used to linearly amplify single-stranded, uracil-containing template prior to 
transformation into high efficiency E. coli. 
1.3. High Throughput Pyrosequencing 
 Traditional DNA sequencing (the Sanger method) is carried out by random 
incorporation of fluorescent-labeled, chain-terminating dideoxynucleotides during 
extension of an oligonucleotide via polymerase (73). DNA fragments are 
separated by length via gel electrophoresis, with the identity of each sequential 
nucleotide determined by the observed fluorophore signal. This technique 
requires a significant quantity of each gene to be sequenced, typically after 
incorporation into a plasmid. 
  28 
 In pyrosequencing, nucleotide addition to an extending chain is detected 
in real-time as the release of a pyrophosphate (74). Nucleotides of known identity 
are added to a reaction mix, and when incorporated, they release a 
pyrophosphate, which is subsequently converted to ATP by ATP sulfurylase. The 
ATP then provides energy for the oxidation of luciferin by luciferase, which 
releases photons in proportion to the number of nucleotides incorporated. In the 
solid phase reaction, excess nucleotides are washed away, while in the liquid 
phase version (75), excess nucleotides are degraded by apyrase. 
 A high throughput version of the pyrosequencing reaction has been 
commercialized by 454 Life Sciences (76). In this version, single stranded DNA is 
first labeled with a short identifying primer, and ligated to small beads. Beads are 
trapped in an oil-water emulsion in the presence of the required enzyme, and the 
reaction proceeds. The emission of light is monitored by a massively parallel 
fiber-optic system. From this data, nucleotide sequence can be determined. In 
the version of the instrument employed here, each individual reaction produces 
read lengths of up to 500 base pairs. Entire TCR variable region sequences 
(~300-350 bp) can thus be determined from a single reaction. 
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CHAPTER 2 
THE ROLE OF FLANKING RESIDUES IN I-AD ASSOCIATED 
OVALBUMIN PRESENTATION TO DO11 
2.1. Introduction 
 The adaptive immune system responds to foreign proteins through the use 
of cytotoxic (CD8+) and helper (CD4+) T cells that activate and direct other 
effectors to mount a protective response. These T cells are activated after a 
productive interaction between the membrane bound T cell receptor (TCR) and 
the surface of cells presenting a composite peptide/major histocompatibility 
complex (pMHC). Crystal structures have revealed regular patterns of peptide-
MHC interactions (77), enabling prediction of peptide epitopes present within 
larger proteins. CD8+ T cells recognize Class I MHC molecules displaying 8-10 
residue long peptides derived from intracellular proteins, proteolytically 
processed to a defined length in order to fit within the closed MHC binding 
groove. In contrast, CD4+ T cells recognize extracellular material that has been 
internalized, processed, and displayed as variable length peptides in complex 
with heterodimeric Class II MHC molecules on professional antigen presenting 
cells. Because of an open-ended peptide-binding groove, class II MHC typically 
display peptides with 13-17 or more residues, with the termini extending out from 
the binding groove (78). These longer peptides present distinct challenges for 
epitope prediction since there are multiple potential modes of interaction with the 
MHC (79, 80). 
 Class II peptides bind the MHC in an extended, polyproline II-like 
conformation, flanked by two antiparallel α-helices, one from each MHC chain 
(81). These helices form a conserved network of hydrogen bonds with the 
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peptide backbone spanning the length of the binding pocket that dictates a 
sequence independent conformation of the displayed peptide. The stability of a 
specific peptide is determined in part by side chain interactions with these helices 
as well as internal binding pockets. The peptide rests atop a series of pleated 
beta sheets, which form four prominent binding pockets, named for the 
respective position within the peptide of the residues that occupy them: P1, P4, 
P6 and P9. The stretch of nine amino acid residues spanning these pockets is 
referred to as the peptide core, and the residues that fill these pockets as anchor 
residues. Considerable effort in class II epitope prediction has focused on 
defining anchor residue preferences for specific MHC alleles (82). The remaining 
residues within the core orient their side chains toward the helices or away from 
the MHC, in order to interact with the TCR. 
 Within the longer peptides presented by class II MHC, multiple core 
sequences may overlap, such that a single pMHC complex may heterogeneously 
present multiple cores for display to responding T cells. Murine class II I-A alleles 
appear particularly susceptible to this phenomenon as anchor preferences are ill-
defined among the diverse set of known binding peptides. The apparent 
degeneracy of I-A alleles emphasizes the need for epitope prediction models 
which incorporate the contributions of separate registers within an epitope.  
Indeed, early sequence-based prediction models found that incorporation of 
flanking residues outside of the predicted core improved predictions for HLA-DQ, 
human homologs of I-A (83). This appears partially attributable to flanking 
residues either interact directly with MHC or influence epitope processing (84). 
More recent models have continued to incorporate flanking residues in sequence 
based prediction models (79, 85, 86), with some explicitly including flanking 
residues for their roles in alternate register binding (79, 80).  
 The I-A allele is associated with numerous autoimmune mouse models, 
while the homologous HLA-DQ allele is associated with insulin dependent 
diabetes milletus, celiac disease, and potentially multiple sclerosis in humans 
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(87, 88). This allele-specific autoimmune susceptibility may result from peptide 
presentation in multiple registers (89). In this proposed mechanism, auto-reactive 
T cells escape thymic deletion because their target self-epitopes are hidden by 
“register masking,” whereby they are presented less frequently than the more 
thermodynamically stable alternate registers within the same proteolytic 
fragment. Thus, T cells responding to the more stable registers are deleted, while 
those responding to less stable registers migrate to the periphery. At the site of 
inflammation, where the peptide is highly expressed, the weaker register will be 
presented with sufficient frequency to activate self-reactive T cells and induce 
disease. Specific epitopes identified in the NOD mouse model of type 1 diabetes 
(90) as well as experimental autoimmune encephalomyelitis (91-93) have been 
identified as potentially susceptible to this mechanism. 
 The DO11 T cell hybridoma is a popular model system used to study 
CD4+ T cell responses, originally elicited by vaccination of BALB/c mice (H-2d 
haplotype) with hen egg white ovalbumin (OVA). The specific peptide recognized 
was originally described as the tryptic fragment corresponding to residues 323-
339 as presented by I-Ad (94). Subsequent studies first identified two distinct 
binding registers within this long peptide (324-332; 327-335) (95). Later, a third 
register was identified (329-337) and a fourth proposed (326-334; Table 2.1) 
(96). Among these, the DO11 T cell hybridoma was shown to recognize the C-
terminal register (residues 329-337, referred to hereafter as register four) through 
the use of N- and C -terminal truncations and targeted amino acid substitutions 
(96). The failure of MHC tetramers with a covalently linked 323-339 peptide to 
stain DO11 and other peptide-specific T cells has driven interest in further 
defining the register recognized. Recently, Landais et al. synthesized four 
tetramers, each presenting one of the four respective nine residue core 
sequences present within the 323-339 peptide, and confirmed that only the 
register four peptide stained DO11 cells and bound the free T cell receptor (97). 
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Table 2.1. Alternate Registers in OVA 323-339 
 Peptide-MHC complex stability correlates broadly with immunogenicity 
(98, 99), as stable epitopes are more prevalent on the cell surface, and 
subsequently more likely to be recognized by responding T cells. Stability is 
commonly approximated as the dissociation rate of fluorescently labeled peptide 
from soluble MHC, although this approach can be complicated by highly 
overlapping registers. McFarland and Beeson showed that OVA registers one 
and three are long-lived and stable (95). Supporting the thermodynamic stability 
of register one, a complex between the 323-339 peptide and I-Ad was crystallized 
in that register (100), and tetramers with long, unhindered covalent linkers 
primarily inhabit register one (97). In contrast, the DO11-responsive register four 
peptide has a very rapid off-rate, with a half-life of around twenty minutes (99). 
To minimize alternate registers confounding this measurement, the amino acid 
sequence flanking the register four core was truncated at P-2 on the N-terminus, 
with the P-2 position altered from valine to lysine, which is presumably too large 
to stably occupy a register one anchor position. These peptide dissociation rates 
predict that register four would behave as a masked epitope, albeit in the context 
of a foreign antigen. Paradoxically, Landais et al. found that pMHC tetramers 
presenting only the fourth register stained a significantly greater number of 
responsive T cells following OVA immunization than tetramers presenting the 
more stable first and third registers. 
 Here, we sought to quantify the extent to which registers one and three 
mask display of the active register four, using synthetic OVA peptides 
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incorporating truncations and/or mutations to alter presentation of a given 
register and, ultimately, enhance register four display. In addition, recombinant 
proteins harboring internal peptide variants were employed to capture effects 
associated with epitope processing. After incubation of DO11 hybridomas with 
corresponding B-cells and one of the antigen variants, we measured T cell 
activation in terms of IL-2 secretion, as the most sensitive determinant of register 
four’s accessibility to responsive T cells.  
 We observed that presentation of register one, but not register three, is 
independent of register four activity. Disruption of register one through N-terminal 
peptide truncation had no impact on activity. Attempts to stabilize register three 
through anchor substitutions in the context of a carrier protein actually increased 
the activity of register four, suggesting that these residues may cooperatively 
enhance display, although the equivalent substitutions in synthetic peptides 
showed no clear effect. Moreover, we provide evidence that register four stability 
has been underestimated by traditional techniques that truncate flanking 
residues. The transfer of flanking residues P-4 through P-2 to an unrelated hen 
egg white lysozyme epitope, HEL11-25, increased the activity of that epitope 
dramatically, suggesting these residues independently stabilize peptide-I-Ad 
interactions. Conversely, additional attempts to stabilize ovalbumin by amino acid 
substitution within the core consistently decreased activity. Collectively, our 
results suggest that in the case of 323-339, flanking residues are vital to activity 
in a previously unforeseen fashion. These results have broad implications for 
class II epitope prediction algorithms and protein engineering efforts to modulate 
protein immunogenicity in therapeutics and vaccines. 
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2.2. Materials and Methods 
2.2.1. OVA and HEL peptides 
 Synthetic ovalbumin 323-339 peptide (p323) was purchased from 
Anaspec (#62571, Fremont, CA). Custom ovalbumin (OVA) and hen egg 
lysozyme (HEL) peptide variants were synthesized by Peptide 2.0 (Table 2.2, 
Chantilly, VA). All ovalbumin variants were amidated at the c-terminus. All 
peptides were 95% pure by HPLC analysis or greater.   
2.2.2. Chimeric malE proteins containing OVA epitopes 
 Fragments of ovalbumin were introduced into the maltose binding protein 
(malE) in a manner similar to that first described by Martineau et al. (101). These 
short peptide sequences were introduced via overlap PCR to replace malE 
amino acid residues 133-140, flanked at the n-terminus by the amino acids 
PDPGSGSG, and at the c-terminus by PDPGS. This extended linker confers 
higher protein expression, along with sufficient length at the n-terminus to 
preclude contributions from residues other than glycine or serine during MHC 
loading. The resulting chimeric proteins were named based on the numerical 
OVA sequence of the inserted peptide. For instance, a chimera containing all 
registers of the OVA peptide is termed malE_323-337. Non-wild type residues 
introduced into malE_327-337 are named with respect to register four positions, 
such that a residue change from valine to methionine at position P-2 is termed 
327 V(-2)M. The modified malE genes were flanked with directional SfiI 
restriction sites and subcloned into pAK400 for periplasmic expression in E. coli 
(102). The plasmid was sequenced to confirm epitope presence, transformed into 
strain BL21, grown overnight at 37 °C in 1-4 L shake flasks. After replacing spent 
media with fresh terrific broth, protein expression was induced with 1 mM IPTG 
for 4-24 hours at 25 C. The cells were harvested by centrifugation and cell pellets 
were resuspended using ice cold 0.1 M Tris pH 7.4-buffered 0.75 M sucrose at 3 
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mL per gram of cell pellet. An osmotic shock to release the periplasmic contents 
was performed by addition or 3 mL 1.0 mM EDTA per gram of cell pellet and 
approximately 0.3 mg/mL lysozyme followed by the addition of 6 mM MgCl2 on 
ice. After an additional centrifugation step, the supernatant was dialyzed against 
10 mM Tris pH 7.4, 0.5 M NaCl with 12-14 kDa MWCO dialysis tubing. Chimeric 
proteins were recovered via immobilized metal affinity chromatography (IMAC) 
with the C -terminal His tag and size exclusion chromatography (Superdex 75; 
GE Healthcare) in HBS and stored at -80 °C prior to use. 
2.2.3. Antigen presenting and T cell hybridoma cell lines 
 The murine A20 B cell lymphoma line presenting I-Ad MHC was acquired 
from ATCC (TIB-208). An A20 variant line with a mutated, non-functional HLA-
DMα gene, 3A5 (103, 104) was transferred from Dr. Kenneth Rock, Dana Farber 
Cancer Institute, Boston, Massachusetts.  The murine DO11 T cell hybridoma 
line was transferred from Dr. Philippa Marrack, National Jewish Health Center, 
Denver, Co. The murine HEL11-25 responsive T cell hybridoma (105) was a 
generous gift from Dr. Andrea Sant, University of Rochester Medical Center, NY. 
All cells were maintained in DMEM supplemented with 10% FBS, 50 Units 
penicillin/ 50 mg streptomycin per mL and 2 mM L-glutamine.  
2.2.4. T cell Activation 
 Each well of a 96-well plate was seeded with 15,000 A20 cells, 15,000 T 
cell hydridoma cells and peptide, malE chimera protein or control peptide/ protein 
per well in DMEM media without L-glutamine, except where noted. After a 24-
hour incubation at 37 °C, 5% CO2, supernatant was transferred to a new plate 
and stored at -80 °C prior to IL-2 quantification assays. All peptide/ protein doses 
were performed in triplicate wells and all experiments replicated at least twice. 
 For malE chimeras and control protein experiments, the relevant protein 
was thawed, filter sterilized, and concentrated using 30K molecular weight cut-off 
centrifugal filter units (Millipore UFC903024).  Proteins were then quantified via 
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absorbance at 280 nm using a predicted extinction coefficient and molecular 
weight, diluted to equal concentrations, the concentration confirmed and serially 
diluted as indicated in the figures. In each well, the volume fraction of protein in 
HBS solution added did not exceed 10%, and an FBS concentration of 10% was 
maintained in all wells. Proteins were pre-incubated for four hours with antigen 
presenting cells (A20 or 3A5) cells prior to a 24-hour incubation with T cell 
hybridomas. The IL-2 concentration in the supernatant was quantified using a 
matched pair ELISA quantified with an IL-2 standard as described (BD #555148). 
All experiments were performed at least twice, and all wells were measured in 
triplicate. Data was analyzed with Graphpad Prism 5 (La Jolla, CA). 
 Glutamine was excluded from experiments (except where noted) to 
minimize cell growth, as preferential growth was observed in inverse proportion 
to T cell stimulation. Since overall IL-2 release is affected by the ratio of T cells to 
B cells, and assays were performed only at a limited number of discrete doses, 
we reasoned that differential growth could potentially mask small differences in 
the activity of specific peptides. The absence of glutamine lowered overall IL-2 
release and required larger concentrations of peptide or protein to reach a given 
release. 
2.2.5. Predicted peptide-MHC docking 
 The coordinates for I-Ad and the OVA 323-334 peptide were extracted 
from PDB 1IAO. The ovalbumin peptide was extended from the c-terminus to 
residue 338 and manually extended such that backbone dihedral angles (φ, ψ) 
approximate those observed in an extended polyproline type II helix (-75, 150). 
Computational peptide docking was performed with ClusPro (106). 
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2.3. Results  
2.3.1. DO11 Activation is Modulated by Epitope Anchor Residue 
Substitutions 
 The rapid dissociation of register four relative to the other registers within 
323-339 led us attempt to increase activity through a corresponding increase in 
its affinity for I-Ad. This poor stability is likely due to the weakly binding anchor 
residues at ovalbumin positions A329, A332, I334, A337 (Table 2.1). Anchor 
substitution is a common technique for increasing the affinity of a given register; 
previously, Chaves et al. reported the relative stability of commonly observed 
anchor residues with I-Ad (107). In this and other work, the interactions of each 
anchor residues with its respective binding pocket were found to be independent 
of the overall sequence (80). 
 Two previous reports described anchor substitutions to stabilize register 
four. Robertson et al. replaced all four positions with the corresponding anchor 
positions from a sperm whale myoglobin epitope with high affinity for I-Ad, using 
the following substitutions: A329E, A332I, I334V, A337S (here referred to as 
peptide 323-339 EIVS) (96), and reported increased activity for the variant. 
Similarly, Lazarski et al. introduced the V327K substitution to prevent register 
shifting as lysine is too large to fit the P1 pocket, as well as A332I and I334V 
(327-339 KIV) (99) and reported recognition by the hybridoma. To assess the 
relative success of these attempts, we synthesized both variants, along with an 
N-terminally truncated version of the Robertson peptide (328-339 EIVS; Table 
2.2) to remove any influence of these flanking residues. To assess peptide 
activity, DO11 hybridomas were incubated for 24 hours with I-Ad+ A20 lymphoma 
cells in the presence of peptide, with the supernatant subsequently assessed for 
IL-2 presence by a matched pair ELISA as a measure of T cell activation.  
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Table 2.2. Modified Ovalbumin and HEL Peptides And Associated EC50 Values.  
EC50 and maximum response values from 3-parameter curve fits of aggregate data from 
multiple (at least two) experiments. Positional numbering is in relation to the active 
register (register four of OVA in this case ). 
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* p<0.01 by extra sum of squares f-test of curve fits for antigen vs. control (MalE 327-337 
for MalE chimeras, HEL11-25 for HEL peptides).  Comparisons performed only on data 
from assays in which both antigens were tested (minimum of two independent assays). 
 ND = not determined  
 Surprisingly, all three peptide variants drastically reduced T cell 
stimulation versus 323-339 (Figure 2.1A). Notably, the full-length peptide with 
anchor substitutions (323-339 EIVS) stimulated more effectively than its shorter 
counterpart (328-339 EIVS). Given the documented affinity increase of 327-339 
KIV for I-Ad (99), the decrease in T cell stimulation with these variants likely 
results from interference in TCR/pMHC recognition due to minor structural 
variations. 
 
Figure 2.1. Specific flanking residues but not alternate register stabilization enhances 
OVA peptide activity. 
 DO11 hybridoma and antigen presenting cells were incubated overnight in the presence 
of exogenous peptide variants, followed by quantification of IL-2 released as a measure of 
T cell activation. A, Wild-type ovalbumin 323-339 () was compared with peptide variants 
modified at anchor residues P4 (A to I) and P6 (I to V) in conjunction with additional 
changes in an effort to stabilize the active register four. Peptide variants include 327-
339KIV () with an additional N -terminal truncation and P-2 modification (V to K) to 
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prevent register shifting; 323-339EIVS () the full-length peptide with all four anchor 
residues altered to strongly binding residues; and 328-339EIVS, an N -terminal truncation 
of the previous variant (). The cell culture media contained 2mM glutamine for this 
assay. B, In a subsequent effort to stabilize register four by removing alternate register 
anchors, the wild-type 323-339 peptide () was compared with N-terminally truncated 
variants 325-337 (n), 327-337 (), and 328-337 (). C, To determine whether peptide 
length is responsible for the activity differences observed in the truncated variants, the 
325-337 variant () which includes register four and the N -terminal P-1 to P-4 residues 
was compared with GGV328-337, in which the P-3 and P-4 positions were replaced with 
glycine () and a further truncated variant, 327-337 (), lacking the P-3 and P-4 residues.  
D, To determine whether binding of register three enhances register four activity, we 
changed the register three P1 anchor residue (also register four P-2) to amino acids 
predicted to stabilize (M) or destabilize (S) register three. We compared three variants 
with identical length: variant GGV328-337 () with a wild-type V versus GGS328-337 () 
and GGM328-337 ().  
2.3.2. DO11 Stimulation Modulated by Residues N-Terminal to P-2 
 The failure of anchor four residue substitutions to increase activity led us 
to explore N-terminal truncations as a means to destabilize alternate registers, 
which may compete with register four for MHC binding. The 323-339 peptide was 
progressively truncated from the n-terminus, with each truncated peptide 
extended to an amidated residue 337 and each peptide variant incubated with 
DO11 and A20 cells, as above. The 325-337 peptide, lacking the P-1 and P1 
positions of register one, conferred identical stimulation in comparison to the 323-
339 peptide, in terms of the 50% effective concentration (EC50) and maximal 
response, suggesting that register one does not effectively compete with register 
four for display (Figure 2.1b, Table 2.2). Additional truncations to remove the 
residues at register four positions P-3 and P-4 reduce activity dramatically; the 
327-337 peptide increases the EC50 nearly 10-fold, from 1.6 to 12 µM peptide 
while the maximal response decreases from 1.1 to 0.7 ng/mL IL-2. For the 328-
337 peptide, activity is so severely reduced that accurate EC50 values could be 
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determined (Table 2.2). These data agree qualitatively with Robertson et al. who 
measured T cell proliferation from transgenic DO11 mice in response to a similar 
set of truncated peptides (96). In contrast to the theorized effects of alternate 
registers in autoimmune peptides, DO11 stimulation is maximal when the entire 
third register and at least one additional N-terminal residue are present, in 
addition to the active register four, which led us to explore the mechanism 
responsible for this enhanced activity. 
2.3.3. Flanking Residue Transfer to HEL1125 peptide 
 A survey of the available crystal structures reveals various roles for N-
terminal flanking residues. The T cell receptor, by virtue of its CDR1α and 
CDR3α loops, often contacts the P-1 position, and can interact with more distant 
residues (77). MHC contacts, on the other hand, appear to be more predictable, 
typically limited to canonical hydrogen bonds between residue P-1 and the side 
chain of β81H or Y, as well as residue P-2 and the main chain of α53 (108). 
 To evaluate the possibility that distant flanking residues of the ovalbumin 
peptide (325-337) were involved in T cell receptor contact, we employed a 
second model system, in which hen egg white lysozyme residues 11 through 25 
(HEL11-25) are presented by I-Ad. This peptide has not been shown to occupy 
multiple frames in I-Ad, but has been characterized as a weak MHC binder with a 
half-life of approximately six hours (99), presumably due to a bulky arginine 
residue which is poorly accommodated by the small P1 pocket. We compared 
the activities of wild type HEL11-25 with variants in which the native P-4 to P-2 
sequence was replaced with OVA-specific residues (QAV13-25) and a control in 
which these three residues were adjusted to GGS (GGS13-25). Since these 
changes lengthen the HEL11-25 peptide by a single amino acid, a control in 
which the HEL11-25 peptide was appended with an N-terminal glycine in position 
P-3 (G11-25) was also analyzed. If the variant including the OVA flanking 
  42 
residues (QAV13-25) showed increased activity, it would decrease the likelihood 
that these flanking residues are specifically interacting with the DO11 TCR. 
 Interestingly, the QAV13-25 variant significantly increases HEL peptide 
activity, with the EC50 decreasing two-fold, from 6 to 3 µM peptide, while the 
maximum response increases two-fold, from 0.7 to 1.5 ng/mL IL-2. In contrast, 
the control peptides exhibit minimal or no change in activity (Figure 2.2; Table 
2.2). The OVA flanking residues at positions P-4 through P-2 independently 
increases peptide activity in a manner independent of the specific T cell 
receptors involved. This supports a direct role for the QAV N-terminal flanking 
residues in stabilizing the peptide-MHC interaction. 
 
 
Figure 2.2. Ovalbumin flanking residues enhance HEL11-25 peptide activity. 
HEL11-25 hybridoma cells and antigen presenting cells were incubated overnight in the 
presence of exogenous peptide variants, followed by quantification of IL-2 release as a 
measure of T cell activation. The wild type HEL11-25 peptide () is compared to a longer 
variant with an additional G at position P-4, G11-25  (); an additional control variant in 
which the P-2 to P-4 flanking residues have been replaced with GGS, GGS13-25 (); and a 
variant presenting the ovalbumin- flanking residues in positions P-4 to P-2, QAV13-25 ().  
2.3.4. Peptide activity is specific to wild type residues N-terminal to P-2 
 We thus sought to clarify the role of residues 325 and 326 in the register 
four interaction with I-Ad. We hypothesized that presentation of register four 
might actually be increased by a stable register three, mediated by rebinding or 
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sliding from the stronger register three to the weaker register four. While the 
more stable register three would be presented more frequently than register four, 
register shifting may provide a mechanism to capture the peptide before it 
diffuses away from the MHC after rapid register four dissociation. In this case, 
residues 325 and 326 would preferentially stabilize register three relative to 
register four, filling the canonical P-2 and P-1 positions for that register, versus 
an uncertain role in stabilizing register four. 
 To assess the possible role of alternate register stabilization, we first 
examined the requirement for specific residues in the flanking positions. 
Published crystal structures show conserved hydrogen bonds between main 
chain amino acids of presented peptides at positions P-1, with the side chain of 
histidine or tyrosine at β81, and P-2, with the main chain of α53. In contrast, 
observed hydrogen bonds and van der Waals interactions between the MHC and 
more distant N-terminal flanking positions are rarer and more irregular, exhibiting 
residue specificity. We replaced the Q325 and A326 residues with glycine in a 
synthetic peptide (GGV328-337). If these residues simply form canonical main 
chain hydrogen bonds in the register three P-1 and P-2 positions then glycine 
substitutions should confer wild type activity. Glycine was selected over alanine 
because of the latter’s propensity to occupy I-Ad anchor positions, as well as the 
presence of alanine at position 326 in the native epitope. The resulting variant 
GGV328-337 was more active than the 327-337 peptide (EC50 = 6 and 12 µM, 
respectively), but remained three-fold less potent than 325-337 (EC50 = 2 µM; 
Figure 2.1C, Table 2.2). Since wild-type peptide activity is modulated by Q325 or 
A326 or both, these residues may instead serve to stabilize register four relative 
to register three. For DO11, peptide activity is somewhat dependent on wild-type 
residues extending at the N-terminus to at least the register four P-3 position 
(residue 326).  
 To specifically probe the impact of register three stability on register four 
activity, we introduced two substitutions for valine at position 327 to modulate 
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register three stability. Among the candidate register three anchor residues 
(V327, A330, A332, N335), the P1 position occupied by V327 is the only anchor 
not overlapping with the register four core (329-337). Previously, residue 
substitutions in the spacious first binding pocket of I-Ad have been shown to have 
drastic impacts on register stability (107). We generated two peptide variants of 
GGV328-337: one in which the valine is replaced with a methionine (GGM328-
337), which shows a strong preference in P1 (30), and a second in which the 
valine is replaced with serine (GGS328-337), which can act as an anchor, but 
poorly occupies P1 (100). If register four competes with register three for MHC 
binding, we would expect peptide activity to inversely correlate with P1 anchor 
preference, such that GGS > GGV > GGM. In fact, we observe a two-fold 
reduced EC50 for GGS328-337, with similar activities for GGV and GGM (Figure 
2.1D; Table 2.2); the role of register three remains ambiguous. Together with the 
substitutions in the HEL peptide, the flanking residue substitutions indicate that 
these residues stabilize register four, at least in part, in a manner independent of 
register three.  
2.3.4. Chimeric Proteins Presenting Variant Peptides Recapitulate Synthetic 
Peptide Results 
 To confirm the peptide results and explore their relevance in the context of 
the native class II peptide display process, we introduced select peptide variants 
into a carrier protein, maltose binding protein (malE). If flanking residues are 
indeed involved in register four stabilization through MHC interaction, then their 
presence should be similarly required in fusion proteins and exogenous peptides.  
However, processing and subsequent presentation has been reported to at times 
eliminate display of weaker pMHC conformers observed during exogenous 
peptide display by means of the MHC class II-like endosomal protein H2-DM 
(105, 109-111). We wondered whether the presentation of register four might be 
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hindered by more stable competing registers when subjected to endosomal MHC 
loading conditions.  
 Peptide sequences were introduced into the exposed loop in place of 
residues 133-140 as first described by Martineau et al. (25), with a gly-ser 
extension (GSGSG) appended to the n-terminus of inserted epitopes to increase 
solubility (Figure 2.3A, Table 2.2). The activity of the N-terminally “truncated” 
peptides (325-337, 327-337, 328-337) maintains the relative preference for wild 
type flanking residues observed with synthetic peptides (Figure 2.3B, Table 2.2). 
The wild-type 323-337 and 325-337 inserts have EC50 within error (13 and 18 µM 
protein, respectively) while the activities of the 327-337 and 328-337 variants are 
greatly reduced (EC50 of 41 and 73 µM, respectively). The increased activity of 
variants retaining the P-3 and P-4 residues of register four during intracellular 
processing again supports their direct role in mediating the peptide and MHC 
interaction.  
 
 
Figure 2.3. Specific flanking residues and register three enhance Ova peptide activity 
when endogenously processed as malE chimeras. 
DO11 hybridoma and A20 antigen presenting cells were incubated overnight in the 
presence of malE chimeras containing ovalbumin epitope variants, followed by 
quantification of IL-2 release as a measure of T cell activation. A, Comparison of wild-type 
peptide 323-337 insert () with N-terminally truncated variants lacking alternate register 
anchor positions: 325-337 (), 327-337 (), and 328-337 (). B, A truncated control 
peptide including the entire register four and register three, 327-337 () was compared 
with variants in which the register three P1 anchor was altered in order to increase this 
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registers stability: 327 V(-2)M () and 327 V(-2)E ().  C, The same control peptide 327-
337 () was compared with malE peptide variants in which the register four P1 anchor 
was altered from alanine to the more stable methionine, 327 A(1)M () and a second 
variant in which the register three anchor positions P1 and P4 were both modified, 327 V(-
2)M A(2)I ().   
2.3.5. Anchor substitution at position 327 enhances peptide activity within 
a carrier protein 
 Presentation of register four may be limited by the more stringent 
competition between a variety of epitopes for MHC binding during peptide 
loading. In general, greater concentrations of the carrier protein are needed to 
achieve equivalent stimulation as exogenous peptides (Table 2.2). In addition to 
the invariant chain peptide, which shows relatively high affinity for I-Ad (112), 
malE itself contains several immunogenic determinants with which the inserted 
epitope must compete (113). We hypothesized that under these conditions, we 
might observe register four dependence on binding of register three. The 
experiments were designed carefully to ensure that any result from the distinct 
processed epitopes is not explicable by differences in solvent exposure or 
protease sensitivity. 
 To test the relationship between register three stability and epitope 
activity, we therefore produced two constructs based on malE 327 with strong P1 
anchors: 327 V(-2)M and 327 V(-2)E.  The negatively charged glutamic acid side 
chain contrasts with the nonpolar methionine in potential contributions to 
solubility and protease accessibility, but both are strongly preferred in the P1 
binding pocket (107). Both substitutions enhanced activity of the processed 
epitope about two-fold, based on EC50 values (18 and 25 µM chimera versus 41 
µM for the native 327-337 fusion protein; Figure 2.3C), consistent with a weak 
effect of register three stabilization on activity. 
 To probe the extent of this observed effect, we create an additional mutant 
to stabilize register three, 327 V(-2)M, A(2)I. In this construct, residue four of the 
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third register was modified from alanine to the anchor residue-preferred 
isoleucine in addition to the previously reported methionine substitution at anchor 
position one. We also attempted to stabilize the active register four in the same 
fashion as register three, by substituting methionine at anchor position one to 
create 327 A(1)M. The single register four anchor variant, 327 A(1)M, did not 
significantly impact activity, while the double register three variant 327 V(-2)M, 
A(2)I eliminated activity (Figure 2.3D). This is consistent with our earlier 
observations with synthetic peptides that anchor residue changes within the 
register four core may compromise T cell recognition. 
2.3.6. Differences in chimera versus peptide activity are not dependent on 
H2-DM 
 During peptide loading onto the MHC in the endosomal compartment, the 
class II-like H2-DM protein modulates the repertoire of displayed peptides (32, 
34). To examine whether the differential activity of our chimeras is a result of H2-
DM activity, we substituted 3A5, a variant of the A20 cell line with an inactivated 
H2-DMα chain (103, 104) in our stimulation assays. While these experiments 
were less sensitive, the relative activities of the peptide variants were consistent 
with A20 experiments for the peptide length controls (Figure 2.4A), and the 327 
anchor substitutions (Figure 2.4B). 
 
 
Figure 2.4. H2-DMα  is not responsible for the different activities of endogenously 
processed peptide variants.  
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DO11.10 hybridoma and 3A5 antigen presenting cells containing mutant H2-DMα  gene, 
were incubated overnight in the presence of malE chimeras containing ovalbumin epitope 
variants, followed by quantification of IL-2 release as a measure of T cell activation. A, To 
assess the effects of removing alternate register anchor positions, truncated ovalbumin 
peptide inserts 325-337 (), 327-337 (), and 328-337 () were compared. B, To assess 
the effect of stabilizing register three with P1 anchor substitutions, the control peptide 
327-337 () was compared with variants 327 V(-2)M () and 327 V(-2)E (), substitutions 
which have been shown to confer enhanced I-Ad binding.  Curve fits for the latter two are 
nearly identical, and lie atop one another. 
 The use of the malE carrier protein to mediate peptide presentation 
supports the role of flanking residues in stabilizing register four presentation, with 
sequence preferences maintained upon intracellular processing in a H2-DM-
independent manner. This supports a role for flanking residues in interacting with 
the MHC, either through stabilizing the recognized conformer or an intermediate 
binding state. Additionally, we find that the processed epitope is more effectively 
presented when register three is stabilized, an effect not seen using exogenous 
peptides.  
2.3.7. Predicted peptide-MHC interactions 
 To further probe the relationship of the binding registers and flanking 
residue interactions with the MHC, we used the molecular docking program 
ClusPro in conjunction with the experimental I-Ad structure to predict peptide-
MHC interactions (106). Subsequent docking of the OVA peptide yielded high 
scoring structures with the peptide oriented in register one as seen in the crystal 
structure, and register three, but neither registers two or four (Figure 2.5).  
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Figure 2.5. Ovalbumin registers one and three are predicted as stably associated with I-Ad 
MHC by computational docking. 
Peptide and MHC coordinates of 323-339 and I-Ad were extracted from PDB 1IAO and 
computationally docked using Cluspro (106). Shown are peptide alignments of the 
register one wild type crystal structure (green) with the high-scoring ClusPro predicted 
register one alignment (blue), and ClusPro predicted register three alignment (yellow). 
Registers two and four were not predicted. 
2.4. Discussion 
 Register masking has attracted increasing attention in recent years as a 
mechanism for promoting autoimmunity via incomplete thymic education. For 
instance, the weakly bound myelin basic protein epitope (MBP Ac1-9) is flanked at 
the C-terminus by a more stable register (91, 92), as well as at the N-terminus in 
the golli-form of MBP expressed in the thymus (93). Maverakis et al. observed 
direct competition between registers for MHC binding, as presentation of each 
register was reduced by the presence of an alternate register. In the non-obese 
diabetic mouse model of type 1 diabetes, the insulin B 9-23 peptide was also 
found to bind in multiple registers (114, 115), with the least stable register 
apparently activating pathogenic T cells (90). By measuring DO11 T cell 
responses in the presence of a series of ovalbumin peptide variants, we 
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demonstrate that the weakly bound fourth register of the ovalbumin 323-339 
peptide is not masked by the two overlapping, more stable registers. In fact, 
responses are maximized when both registers three and four are present. This 
contrasts with the current view of register masking and we thus aimed to 
understand the roles of alternate registers in DO11 activation as a potentially 
novel mechanism to enhance and stabilize the display of weakly bound peptides. 
 Of the four registers present within the ovalubumin 323-339 peptide, the 
first register (residues 324-332), forms the most kinetically stable complex with 
MHC (95), is preferentially presented in I-Ad tetramers (97), and in the I-Ad crystal 
structure (100). Ovalbumin peptides with N-terminal truncations to position 325 
no longer occupy the first register, due to the absence of the register one P1 
anchor and P-1 flanking residue (95). Yet, in the presence of the responsive 
DO11 hybridoma, the resulting 325-337 peptide is no more active than the full-
length version, indicating that register one does not competitively inhibit display 
of the active register four. In contrast, the presence of an intact register three 
enhances peptide activity relative to the isolated register four: the activity of the 
short 328-337 peptide is lower than that of the 327-337 peptide, which is in turn 
lower than the 325-337 peptide. Our efforts to alter register three stability through 
anchor one substitutions showed no clear effect for exogenous peptide, while 
activity did correlate with predicted stability for epitopes inserted into the malE 
carrier protein. The latter result occurs in a system designed to replicate natural 
protein processing, and seems to indicate a “piggybacking effect,” in which 
display of a weaker binding register is enhanced by the presence of a stronger, 
overlapping register. Since activation requires recognition of peptide by both the 
MHC and the TCR, a register weakly bound by MHC might be immunodominant 
if it presents a composite peptide-MHC surface readily recognized by a variety of 
T cell receptors. Indeed, our findings are consistent with the surprising finding of 
Landais et al. that the weakly bound register four is the immunodominant register 
(97).  
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 However, register four activity does not appear to be entirely dependent 
on the piggybacking of register three. Our data suggests that previous efforts to 
measure register four stability, in which the peptide was truncated at the register 
four P-2 position, with P-2 itself altered from a valine to a lysine to prevent 
register shifting (327-339 KIV) (99), underestimated the value for the native 
register. Moreover, substitution of the register four P-4 and P-2 residues into the 
distinct I-Ad epitope HEL11-25 dramatically increases peptide activity when 
presented to a responsive T cell hybridoma. Within the available peptide/MHC 
crystal structures, flanking residues typically form hydrogen bonds and van der 
Waals contacts with the MHC, which would stabilize weak registers. These 
interactions are commonly seen out to P-2, and occasionally to P-3 and beyond 
(116-122). In the ovalbumin case, the register four P-4 to P-2 flanking residues 
are also employed as the register three P-2 to P1 residues (Table 2.1). Thus, 
efforts to measure the stabilizing effects of these residues on register four will be 
obscured by the presence of the intact register three with a slower dissociation 
rate. In summary, analysis of synthetic peptides shows no clear correlation 
between register four activity and register three stability. This may be due the 
reduced hybridoma sensitivity to peptides versus endosomally processed protein, 
increased register three stabilization eventually negatively competing with 
register four or the flanking residues stabilizing register four via a register three-
independent mechanism. 
 An alternative explanation for the apparently co-operative interactions of 
registers three and four is that they form a single, larger register as opposed to 
two distinct, yet overlapping registers. Several lines of evidence refute this 
hypothesis. First, McFarland and Beeson convincingly demonstrated the 
existence of register three through the use of an amino acid substitution at P2 
(H328Q), which forms a dissociation intermediate with the MHC. Second, use of 
the ClusPro docking program to predict interactions between the ovalbumin 323-
339 peptide and empty I-Ad molecules rank register three as highly stable (Figure 
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2.5). Third, register four has been independently proposed multiple times: by the 
Marrack-Kappler group (personal communication), Robertson et al., and Landais 
et al. In the latter report, I-Ad tetramers covalently linked to the register four nine 
amino acid core, but not those linked to register three, bound and activated 
DO11 T cell hybridomas. In our hands, the free peptide consisting of the nine 
amino acid core was sufficient to activate DO11, albeit at extremely high 
concentrations (data not shown). 
 Our finding that the anchor substituted peptide 323-339 EIVS severely 
diminished activity contrasts with the finding of Robertson et al. Many reports 
have described successful increases in biological activity via anchor swaps, 
particularly for CD8+ T Cells (123-129). However, the effect seems far from 
general, as several other reports have shown the opposite effect include (116, 
130-132) Notably, our work is consistent with Landais et al., who generated I-Ad 
tetramers with the register four 329-337 peptide and observed reduced DO11 
staining when the chemically distinct P1 substitutions A329M or A329E were 
introduced (97). The discrepancy with Robertson et al. may be attributable to 
assay differences: measurement of hybridoma IL-2 secretion versus their DO11 
transgenic T cell proliferation. In summary, this result highlights the sensitivity of 
the DO11 TCR to even small conformational changes introduced within the core. 
 A key outstanding question is the mechanism by which stronger registers 
competitively inhibit display of the masked register in myelin basic protein (93), 
yet appear to co-operatively enhance display of ovalbumin register four. One 
possibility is that the relative stabilities of the ovalbumin registers are similar, and 
the registers highly overlapped, such that the energetic costs of peptide transfer 
between registers three and four are small. This sliding or rebinding mechanism 
could prevent peptide loss due to rapid register four dissociation and subsequent 
peptide diffusion away from the antigen-presenting cell. Alternatively, the I-Ad 
molecule itself, with its small, hydrophobic anchor pockets, may be more 
permissive to register shifting. 
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 Overall, our findings support inclusion of residues outside the nonameric 
core and multiple, distinct registers in epitope prediction models (79, 80, 85, 86). 
The ability of ovalbumin flanking residues to confer enhanced activity to an 
unrelated HEL11-25 peptide may have general applications for understanding 
peptide immunogenicity and stability. In terms of the specific ovalbumin 323-339 
peptide, our attempts to increase peptide activity through register four anchor 
substitutions severely diminished activity. Anchor substituted peptides may be 
more prone to influencing T cell response, as compared to flanking residue 
changes which are more distal to primary T cell contacts. In contrast, 
modification of flanking residues may increase activity of a weakly bound peptide 
while minimizing changes in the responding T cell repertoire. Recently described 
high throughput techniques (133), are likely to be instrumental in identifying 
stabilized variants of weakly bound peptides for use as altered peptide ligands in 
autoimmune therapies and vaccines. 
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CHAPTER 3 
T CELL RECEPTOR ENGINEERING 
3.1. Introduction 
 The primary goal of this work was the creation of a soluble, high-affinity 
version of the DO11 T cell receptor for the detection of ovalbumin displayed by 
the murine MHC, I-Ad. Secondary focus was given to the manipulation of 
expression and display systems toward generality in the display of other T cell 
receptors. Consideration was also given to tethering of immunoactive peptides to 
soluble constructs. 
3.1.1. Single-Chain T Cell Receptors 
 The creation of T cell receptor reagents requires modification from their 
native membrane-bound form. This modification has taken several forms 
including the single chain T cell Receptor (scTCR), the disulphide-linked T cell 
Receptor (dsTCR), and c-jun/v-fos leucine zipper-linked TCRs (Figure 3.1). A 
single-chain TCR is made up of the smallest functional unit of the T cell receptor, 
its α and β chain variable regions connected by a flexible linker. The scTCR 
mimics a popular antibody creation, the scFv, which has been applied 
extensively in the development of antibody therapeutics. The extracellular 
regions of membrane-bound TCRs are structurally homologous to antibody 
fragments, comprised of two chains and four immunoglobulin domains (two 
constant, two variable, with the variable (V) regions responsible for engaging 
ligand. The first scTCR was created by Novotny et al. (134), and many have 
since been attempted.  
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Figure 3.1. T Cell Receptor Expression Constructs.  
 Previously, DO11 has been expressed solubly in insect cells by a 
construct consisting of full DO11 chains (α and β chains with variable and 
constant regions) truncated just prior to the transmembrane portion of the 
constant domain (135). The dsTCR follows this general pattern, but introduces a 
non-native disulphide bond introduced between constant regions (136). Others 
have opted for the inclusion of a leucine-zipper region rather than a disulphide 
bond (137). The interaction between these chains has been reported to stabilize 
the molecule. While both the leucine zipper and dsTCR constructs produce large 
quantities of soluble TCRs, both also rely on the refolding of aggregated 
intracellular inclusion bodies when expressed in bacteria. Inclusion bodies are 
insoluble accumulations of improperly folded protein in the cell, and correlate 
negatively with the phage display of fusion proteins.  
 Described here is the production of scTCRs solubly in bacterial cytoplasm 
followed by export to the periplasm and release upon osmotic shock. Soluble 
expression in the robust, fast-growing bacteria is inexpensive and allows for 
relatively rapid evaluation of mutant constructs. This work shows that this method 
is far from generalizable, but highly useful in specific instances, as is the case for 
DO11. 
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3.1.2. Multimerization and Affinity Maturation 
 The utility of scTCRs as reagents is dependent upon overcoming inherent 
low-affinity binding to substrates, typically between 5-100 µM (138), which is 
relatively weak in comparison to the low to sub-nanomolar affinities routinely 
found in antibodies. Multimerization employs multivalent constructs to increase 
the overall avidity of a reagent, whereas affinity maturation is seeks to directly 
increase the affinity of the monomer. 
 Affinity is quantified as the dissociation constant of the TCR/pMHC 
complex, Kd = koff/kon.  
 
Affinity maturation is routinely achieved for scFvs, but work with soluble TCRs 
has been limited for the most part to work done by two groups. Kranz and 
colleagues have worked extensively with a yeast display system in engineering 
the 2C class I system, and more recently, the 3.L2 class II system (139). Yeast 
display was used to select for thermally stable variants of the 2C scTCR (140) 
and improve its affinity 100 fold, to 9 nM (141). These higher affinity mutants, 
however, showed high cross reactivity to self-peptide/ MHC (142). Later work did 
indeed generate high affinity, highly- specific TCRs been generated through 
yeast display, for the 2C (143) and 3.L2 scTCRs (139). Recently, an scTCR 
based on the 2C scaffold was shown to be affinity-matured through display on a 
hybridoma via retroviral infection (144). The maturation of 3.L2 represents the 
only instance of maturation towards a Class II pMHC target of which we are 
aware.  
 Phage display of only the Vα domain of a TCR was originally reported in 
1995 (145), with display of a functional TCR was first reported shortly thereafter 
by Weidanz et al. (146).  These authors displayed DO11 as three-domain scTCR 
(including the constant β region), and demonstrated activity, but no affinity 
maturation was reported. Since then, affinity maturation via phage display has 
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been reported for three TCRs. For A6, expressed as a dsTCR (147), affinity was 
improved from about 32 µM to 26 pM against a viral Class I pMHC, and the 
matured TCR showed no cross-reactivity to non-specific peptides. Of note, the 
A6 TCR was also later affinity matured through rational design based on the 
known crystal structure (148). Maturation of the 1G4 dsTCR against a tumor-
associated class I antigen was later shown strictly through the introduction of 
CDR2 mutants (149). Despite the canonical association of CDR2 with the MHC, 
variants were shown to be peptide-specific. A third TCR, specific to the class I-
restricted SL9 antigen of HIV was isolated from a T cell line and affinity matured 
against its target through CDR2β and CDR3α mutations, giving an increase from 
a wild type Kd of 143 nM to less than 400 pM. 
 Multimerization is typically accomplished through the natural interaction of 
four biotins with a single avidin variant. MHC tetramers, in which the C-termini of 
each MHC molecule is singly biotinylated followed by complexation with avidin, 
have been utilized so extensively in characterization of T cell specificity that an 
entire NIH facility exists to manufacture these reagents (for review: (150)). 
Tetramers have been created previously for TCRs in the context of dsTCRs 
(151) and leucine-zipper heterodimers (152). Both reports showed an effective 
increase in TCR avidity as a result of multimerization. Laugel et al. demonstrated 
that tetramers of the A6 TCR can compete with cytotoxic lymphocytes for binding 
to antigen presenting cells in vitro. Both of these cases utilized TCRs with 
relatively high affinity to mitigate the affects of naturally low levels of antigen 
display. 
 In this work we demonstrate the affinity maturation of DO11 against KJ1-
26 through the use of phage display. The clonotypic antibody KJ1-26 was used 
as a proxy for ova 323-339/I-Ad constructs because of previously documented 
issues with the soluble, covalently-linked pMHC reagent. This antibody was first 
isolated as binding DO11 (153), and later shown to isolate a single distinct T cell 
hybridoma from a group of 397 hybridomas isolated from BALB/c T cells (154). 
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The isolated hybridoma, 7DO-286.2 was shown to share fine specificity with 
DO11. Given this specificity for the binding site of DO11, we hypothesized that it 
mimics the pMHC surface and could serve as a pMHC proxy during DO11 affinity 
maturation by directed evolution. 
 After maturation, we demonstrate multimerization of the scTCR and its 
matured variant through natural binding of a monoclonal antibody to an EE 
epitope tag inserted into the construct. The resulting dimer was then further 
complexed to a fluorescently labeled IgG1, and used to stain A20 cells. The DO 
variant “176” showed labeling activity based on the presence of 323-339 peptide. 
3.1.3. Therapeutic Applications 
 High affinity variants of DO11 have potential for in further exploring the 
antigen presentation of ovalbumin by I-Ad. In addition, affinity matured TCRs as 
a class may be useful in diagnostics and treatment of cancer, viral infection, and 
autoimmunity either in soluble form (Reviewed: (155), (156)), or transduced into 
the T cells of an individual patient (157). Class II reactive TCRs are uniquely 
suited for targeting antigen-presenting cells in autoimmune conditions, which are 
mediated by CD4+ T cells. The multitude of issues involved in such a treatment 
(necessary ligand density, peptide specificity of the reagent, immunogenicity of 
the construct) are beyond the scope of this work. We do, however, demonstrate 
that the fusion of a human IL10 (IT9302) mimic peptide shown to possess many 
of the immunosuppressive functions of the cytokine (158-160) can be produced 
as a conjugate to a 172 TCR in soluble bacterial expression at high levels (>30 
mg/L). Cytokine tethering would seem ideally suited for TCR targeting, based on 
the association of both with antigen-presenting cell based receptors, and 
potential side effects associated with global circulation. 
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3.2. Materials and Methods 
3.2.1. Single Chain T Cell Receptors 
 Full chain T Cell receptor genetic material was obtained from various 
sources. 2B4, 2C, 172.10, 1934.4 G206, and D10 were gifts from KC Garcia, 
Stanford University. 2D1 was a gift from Lars Fugger, Cambridge University. The 
3B6 and 4C4 T Cell Lines were gifts from Thomas Forsthuber, University of 
Texas- San Antonio. Lymph Nodes from a DO11 transgenic mouse were a gift of 
Marc Jenkins, University of Minnesota. When necessary, total RNA was isolated 
from relevant cells using Invitrogen’s PureLink Micro to Midi Total RNA 
Purification System (12183-018, Carlsbad, CA), or Qiagen’s RNeasy Mini Kit 
(#74104, Gaithersburg, MD). Alpha and beta variable regions were connected via 
a (Gly4Ser)4 linker using overlap PCR and gene-specific oligonucleotides. 
Fusions of various peptides to the N- and C- terminus of scTCR constructs were 
synthesized using short oligonucleotides (<60 bp) and incorporated into scTCRs 
using overlap PCR. 
 After amplification using flanking primers incorporating directional SfII 
restriction sites, scTCR constructs were PCR purified (Qiagen #28104), digested 
with SfiI (New England Biolabs #R0123, Ipswich, MA) at 50 °C for greater than 3 
hours, separated on a 0.8% agarose gel and purified using a QIAquick Gel 
Extraction Kit (#28704). Purified scTCR DNA was then mixed with similarly 
purified expression plasmid at between three and five to one molar ratio and 
ligated using New England Biolabs’ T4 DNA Ligase (#M0202) at 16 °C for 
greater than one hour. Following transformation into XL1B E. coli strain, plasmids 
were isolated from individual colonies using a QIAprep Spin Miniprep Kit 
(#27106) and sequenced to confirm incorporation. 
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3.2.2. Plasmids and Phagemids 
 Plasmids pAK400 and pAK500 were a gift from Andreas Pluckthun, 
University of Zurich. The phagemid pMoPac24 was a gift from George Georgiou, 
The University of Texas at Austin. 
 Phagemid pMoPac24 was modified to express variants of M13 Gene 
Product VIII (pVIII) in the place of gene product III (pIII). Gene VIII fusion protein 
and it’s variants were synthesized by amplification of 50-60 bp overlapping 
oligonucleotides with flanking primers incorporating 5’ Asc I and 3’ HindIII 
restriction sites. As with the original gene PCR products were purified, digested 
at 37 °C for than 1 hour, separated on a 2% agarose gel and gel purified. 
Following transformation in XL1B E. coli, plasmids were isolated from individual 
colonies and sequenced to confirm incorporation. 
 Plasmid pAK400 was modified to express peptide fusion peptide IT9302 
through by full plasmid amplification. The plasmid was methylated using CpG 
methyltransferase (NEB #M0226) at 37 °C for greater than one hour. 
Oligonucleotides incorporating the insertion with at least 18 bp showing 
complementarity to the site of insertion were phosphorylated using T4 
polynucleotide kinase (NEB #M0201) for at least one hour at 37 °C. 
Phosphorylated primers were then used to amplify the plasmid in PCR. Following 
amplification, the original plasmid was digested with DpnI (NEB #R0176) at 37 C, 
and the amplified plasmid ligated using T4 DNA Ligase (NEB #M0202) prior to 
transformation in the XL1B strain of E. coli. 
3.2.3. Protein Expression 
 Sequenced plasmids containing scTCR genes were transformed into the 
strain BL21, grown overnight at 25°C in baffled shake flasks ranging from 500 mL 
to 4 L. After replacing spent media with fresh terrific broth, protein expression 
was induced with 1 mM IPTG for 4-24 hours at 25 °C. The cells were harvested 
by centrifugation and cell pellets were resuspended using ice cold 0.1 M Tris pH 
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7.4-buffered 0.75 M sucrose at 3 mL per gram of cell pellet. An osmotic shock to 
release the periplasmic contents was performed by addition or 3 mL 1.0 mM 
EDTA per gram of cell pellet and approximately 0.3 mg/mL lysozyme followed by 
the addition of 6 mM MgCl2 on ice. After an additional centrifugation step, the 
supernatant was dialyzed against 10 mM Tris pH 7.4, 0.5 M NaCl with 12-14 kDa 
MWCO dialysis tubing. Chimeric proteins were recovered via immobilized metal 
affinity chromatography (IMAC) with the c-terminal His tag and size exclusion 
chromatography (Superdex 75 or 200; GE Healthcare) in HBS and stored at -80 
°C prior to use. 
3.2.4. Biotinylation of scTCRs  
 Purified scTCR tagged with a biotinylation site was concentrated to at 
least 40 µM using centrifugal concentration. Proteins were biotinylated using 
biotin protein ligase (BirA, Avidity, Denver, CO) by incubating overnight at room 
temperature. Protein was then purified by size exclusion chromatography 
(Superdex 75 or 200; GE Healthcare) in HBS and concentrated. Biotinylation was 
evaluated by mixing with equimolar extravidin (Sigma #E2511), separating on 4-
20% SDS-Page gradient gel, and detecting via α-His HRP western blot. 
3.2.5. Preparation of EE-Tagged Dimers and Tetramers 
 Epitope tags were inserted into specific proteins using overlap PCR as 
described above. When necessary, proteins were concentrated to 3-5 mg/mL 
using a centrifugal system. Proteins were quantified using a commercial 
bicinchoninic acid assay (Pierce #23227, Rockford, IL) and by absorbance at 280 
nm in conjunction with a theoretical extinction coefficient. Dimers were prepared 
from proteins containing the “EE” epitope tag (amino acid sequence EYMPME) 
by stepwise addition of the monoclonal antibody specific to that tag (Covance 
#MMS-115P, Princeton, New Jersey). Monoclonal antibody was added to a 1:2 
molar ratio in a series of 6-10 individual steps, separated by 10 minutes. 
Tetramers were prepared by addition of α−IgG1 monoclonal antibody (clone x56, 
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BD Pharmingen #550874) specific for α-EE, fluorescently labeled with 
allophycocyanin (APC). This antibody was added to dimerized proteins in an 
additional series of stepwise additions at a 1:2 molar ratio to the initial antibody. 
3.2.6. Flow Cytometry 
 A20 cells expressing I-Ad were incubated with specific doses tetramerized 
scTCR or maltose binding protein control along with specific doses of peptide.  
Incubation was carried out at 4 °C in in Hepes buffered saline with 1% FBS for 2-
4 hours. Allophycocyanin staining of cells was measured using an LSR II 
Fortessa flow cytometer (BD Biosciences), stimulated at 635 nm, with 
fluorescence measured after emitted light passed through a 670/30 band-pass 
filter. Data were analyzed using FlowJo 9.4.9 (Tree Star, Inc.; Ashland, OR). 
3.2.7. Phage Production 
 XL1-B cells containing phagemid were grown in baffled erlenmeyer flasks 
at 37 °C in the presence of 200 µg/mL ampicillin and 10 µg/mL tetracycline to 0.5 
OD600, 25 mL to 1L total volume. M13KO7 was added at a multiplicity of 
infection (MOI) of greater than one along with 1 mM IPTG and cultures continued 
to shake for 2 hours at 37 °C. Kanamycin was then added (50 mg/mL), and 
culture temperatures were lowered to 25 °C, where they were allowed to shake 
for up to 24 hours before harvest. 
3.2.8. Phage Purification 
 Supernatants from XL1-B cultures were collected from cultures were 
collected following 3,000xg centrifugation for 30 minutes. Phage were 
precipitated by the addition of one fifth volume of 2.5 M NaCl, 20% w/v PEG 
8000 to supernatants, followed by 1 hour incubation at 4 °C. Phage were 
collected by after centrifugation of supernatants (3000xg for at least one hour), 
and resuspended in 1 to 2 mL HBS. Resuspended phage were then centrifuged 
in at 16,000xg for a minimum of 10 minutes to remove subcellular debris. Phage 
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were then precipitated again with 1/5 volume 2.5 M NaCl, 20 % w/v PEG 8000 
and resuspended in 0.5 – 1 mL HBS. 
3.2.9. Library Construction 
 A library of DO11 CDR3α variants was produced according to the protocol 
of Weiss et al. (72). DO11 scTCR in pMoPac24 was modified to include three 
consecutive stop codons starting at amino acid position 107 (IMGT numbering) 
by quick change PCR, as previously described. 
  Two libraries were constructed to produce libraries of 8 and 10 amino acid 
CDR3α lengths. Oligonucleotides were synthesized to randomize six codons of 
DO11 CDR3α, from either amino acid 107 through 115 (ten amino acid library) or 
106 through 116 (eight amino acid library). Each oligo included 18 nucleotides 
flanking the random codons that were identical to wild type DO11. Random 
codons were coded as NNS, where “N” corresponds to any of the four-nucleotide 
bases and “S” is guanine or cytosine. 
 Single-stranded DNA template was isolated from phage particles. CJ236 
E. coli transformed with pMoPac24 containing DO11 with stop codons in its 
CDR3α was grown in 1 mL of terrific broth containing 0.25 µg/mL uridine, 34 
µg/mL chloramphenicol to select for the F’ episome, 200 µg/mL ampicillin to 
select for the phagemid, and 1% glucose. When the cells reached 0.5 OD600, 
they were infected with M13K07 helper phage, continued to grow for 1 hour, and 
scaled up to 30 mL terrific broth containing 50 µg/mL kanamycin. Cells were 
allowed grown overnight at 37 °C with 200 rpm shaking. Phage were harvested 
as before, precipitated, and resuspended in 0.5 mL PBS. Approximately 20 µg of 
single-stranded DNA was purified from this phage using a QIAprep M13 Spin Kit 
(#27704). DNA produced from CJ236 contains a significant amount of uracil in 
place of thymine.  
 The library was then created from by extension around a dU-ssDNA 
template with randomized oligonucleotides. Oligos were phosphorylated with T4 
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polynucleotide kinase, and mixed with template in approximately a 3:1 molar 
ratio. The mixture was heated to 90 °C in a thermocycler for 2 minutes, cooled to 
20 °C over the course of four minutes, and allowed to incubate at five minutes at 
20 °C. The annealed oligo was extended around the plasmid using T7 DNA 
polymerase and ligated with T4 DNA ligase while incubating overnight. The 
resulting template was then transformed into electrocompetent XL1-B, which 
preferentially replicates the newly synthesized strand lacking uridine. 
3.2.10. Affinity Maturation 
 XL1-B cells containing DO11 CDR3α library were grown up and phage 
were produced and purified as described above (3.2.6 and 3.2.7). Between 108 
and 1010 cfu were added to immobilized KJ1-26 or irrelevant antibody in 96-well 
plates and allowed to incubate for 2 hours at 37 °C with gentle shaking. Cells 
were then washed five times with PBS and eluted with 50 mM glycine pH 2.2. 
Eluted phage were rapidly neutralized with 2 M Tris, and infected into 2 mL 
ER2738 cells at 0.5 OD600 growing in 2xYT with 10 µg/mL tetracycline for 30 
minutes at 37 °C with shaking. Following infection, these cells were scaled up to 
100-500mL TB containing 200 µg/mL ampicillin and 50 µg/mL kanamycin, 1 mM 
IPTG, and 0.1% glucose. This media lacked tetracycline, to prevent cross 
infection of library variants. Cells were shaken at 37 °C until approximately 0.5 
OD500, then cooled to 25 °C and permitted to shake overnight. The following 
day, phage was purified and another round of panning performed. 
3.2.11. Antibodies and Peptides 
 Synthetic ovalbumin 323-339 peptide (p323) was purchased from 
Anaspec (#62571, Fremont, CA). α−M13 HRP was purchased from GE 
Healthcare (#27-9421-01). KJ1-26 was purchased from BD Pharmingen 
(#551771). α-his HRP was purchased from Invitrogen (R931-25, Carlsbad, CA). 
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3.2.12. Oligonucleotides 
 All oligonucleotides were purchased from IDT (Coralville, Iowa). 
3.2.13. Antigen presenting and T cell hybridoma cell lines 
 The murine A20 B cell lymphoma line presenting I-Ad MHC was acquired 
from ATCC (TIB-208). The murine DO11 T cell hybridoma line was transferred 
from Dr. Philippa Marrack, National Jewish Health Center, Denver, Co. All cells 
were maintained in DMEM supplemented with 10% FBS, 50 Units penicillin/ 50 
mg streptomycin per mL and 2 mM L-glutamine. 
3.2.14. Inhibition of T Cell Activation 
 Each well of a 96-well plate was seeded with 15,000 A20 cells, 15,000 T 
cell hydridoma cells, 20 µM ovalbumin peptide, and specified concentration of 
M13 bacteriophage wild type or displaying specified proteins in each well with 
DMEM media without L-glutamine. After a 24-hour incubation at 37 °C, 5% CO2, 
supernatant was transferred to a new plate and stored at -80 °C prior to IL-2 
quantification assays. All phage concentration doses were performed in triplicate 
wells and all experiments replicated at least twice. In each well, the volume 
fraction of phage in HBS solution added did not exceed 20%, and an FBS 
concentration of 10% was maintained in all wells. The IL-2 concentration in the 
supernatant was quantified using a matched pair ELISA quantified with an IL-2 
standard as described (BD #555148). Data was analyzed with Graphpad Prism 5 
(La Jolla, CA). 
 Glutamine was excluded from experiments (except where noted) to 
minimize cell growth, as preferential growth was observed in inverse proportion 
to T cell stimulation. Since overall IL-2 release is effected by the ratio of T cells to 
B cells, and assays were performed only at a limited number of discrete doses, 
Ireasoned that differential growth could potentially mask small differences in the 
activity of specific peptides. The absence of glutamine lowered overall IL-2 
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release and required larger concentrations of peptide or protein to reach a given 
release. 
3.2.15. Assessment of scTCR Binding Affinity Using BIACore 
 Kinetic binding assays were performed with scTCRs and KJ1-26 using a 
BIAcore 2000 (GE Healthcare). KJ1-26 were coupled to CM5 chips using NHS-
EDC chemistry to a level of ~600 RU. The signal from a flow cell coupled with a 
control protein (BSA) was used to correct for non-specific binding to the matrix. 
scTCRs were injected in a duplicate two-fold dilution series from 400  nM at a 
flow rate of 35 µl/min. The association rate constant (kon), dissociation rate 
constant (koff), and equilibrium dissociation constant (Kd; Kd = koff/kon) were 
calculated assuming a Langmuir 1:1 binding model with BIAevaluation software.  
3.3. Results 
3.3.1. Cloning of Single Chain T Cell Receptors 
 Single chain T cell receptors were assembled from genetic material of 
various origins. Variable regions were isolated and joined on either side of a 
flexible linker made up of repeating gly-ser subunits. The resulting scTCRs were 
cloned into application-specific members of the pAK vector series. These vectors 
were originally developed in the Pluckthun lab (65), and offer convenient shuttling 
of genes between gene III phage display on M13 and periplasmic protein 
expression driven by a lacZ promoter. The two primary vectors used in this work 
are pAK400 and pMoPac24. For the purposes of periplasmic expression of 
soluble, pAK400 connects the inserted gene to a pelB leader sequence at the N- 
terminus and a hexa-histidine tag (6xHis) at the c-terminus via a directional Sfi I 
sites (Figure 3.2). Translated proteins are transported into the periplasm via the 
pelB leader, where they are cleaved and released following osmotic shock. The 
histidine tag then allows for convenient purification via affinity to divalent cations, 
also known as immobilized metal affinity chromatography. pMoPac24 was 
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derived from the pAK400 vector by Hayhurst et al. (161), who modified it by 
connecting the inserted gene to a short version of M13 gene III (isolated from 
pAK100), coexpressing the seventeen kilodalton protein (Skp), and substituting 
ampicillin for chloramphenicol resistance. Ampicillin resistance is useful in 
conjunction with the chloramphenicol-resistant CJ236 cell line used in library 
generation. 
 
Figure 3.2. pAK400 Schematic. 
ScTCRs to be expressed were cloned in place of the tet cassette with directional SfiI 
restriction sites. (Source: (102)). 
 A representative list of the scTCRs studied for this work is shown in Table 
3.1. Receptors such as DO11, 2B4, and D10 were among the first hybridoma 
models created from mouse T cells, and continue to be well studied as mouse 
models. Others are of particular interest in autoimmunity, having been isolated as 
autoreactive T cells in particular mouse models of type I diabetes (G206), and 
multiple sclerosis (172.10, 1934.4, 4C4, 3B6). DO11 is of primary interest due to 
its ovalbumin target, while the remainder are included to illustrate the generality 
(or lack thereof) of the documented platforms. 
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Table 3.1. T Cell Receptor Origins, Antigens, and Single Chain Expression Level. 
3.3.2. Protein Expression 
3.3.2.1. TRBV13-2 Associated Stability  
 Single-chain T cell receptors in pAK400 were transformed into the E. coli 
strain BL21, which is commonly used for protein expression due to its rapid 
growth characteristics and deficiency for the proteases ompT and lon. Cells were 
typically induced for between 12 and 20 hours prior to harvest. Proteins were 
isolated by osmotic shock and purified by binding of the histidine tag to Ni2+ 
associated sepharose beads and subsequent FPLC size exclusion. The 
expression of various scTCR constructs is shown in Table 3.1. In general, we 
found high-level protein expression is associated with receptors incorporating the 
TRBV13 (alternately known as Vβ8) variable region. This expression is 
dependent upon both the orientation of the chain with respect to its associated 
alpha chain. 
 Four amino acid changes have previously been reported to stabilize the 
TRBV13-2 chain. The G17E mutation was selected in for in a randomly 
generated yeast display designed to improve expression of the 2C scTCR (162). 
Similarly, the H54Y mutant was selected in 2C from a yeast display library 
subjected to thermal stress (140). Two other mutants, I90T and L93S, were 
reported as having been originally identified to improve expression in E. coli 
(163). All amino acid numbering is according to IMGT standards. The 
incorporation these four substitutions into the D10 scTCR resulted in a marginal 
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increase in expression, and the emergence of a well defined monomer peak in 
size exclusion purification (Figure 3.3), but still yielded low overall levels of 
expression. Reversing the orientation of the chains, such that the beta chain was 
located upstream of the linker increased production by greater than an order of 
magnitude. Expression of DO11 reinforced the necessity of both solubility 
inducing mutations and β-linker-α orientation, as the orientation alone was 
insufficient to induce high-level expression. 
 
Figure 3.3. Orientation and Solubility-Mutant Effects in Production of DO11 and D10 
scTCR.  
Protein was purified from 100 mL BL21 E. coli culture by osmotic shock and Ni+2 resin 
prior to column purification. Top Left, Chromatogram of original D10 construct with Vα-
linker-Vβ  orientation and lacking solubility- inducing mutations, induced for four hours. 
Top Middle, D10 with the addition of four solulbility inducing point mutations in TRBV13-2 
after four hour induction. Top Right, Expression levels following reversal of chain order 
and 24 hour induction. Bottom left, DO11 scTCR in reverse orientation, lacking solubility 
inducing mutations, 20 hour induction. Bottom Middle, DO11 in reverse orientation with 
solubility inducing mutations. The arrow indicates location of the monomer.  
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 The functionality of DO11 was demonstrated by binding KJ1-26, which 
recognizes the binding sites of properly paired DO11 alpha and beta chains. 
DO11 showed a dose dependent response to immobilized KJ1-26, as detected 
by α−His conjugated to HRP (Figure 3.4). The protein also appears to be stable, 
as heat treatment at 37 °C for up to 90 hours showed no decrease ELISA 
response (data not shown). 
 
Figure 3.4. DO11 scTCR is Recognized by KJ1-26 α-Idiotype Antibody.  
ELISA Plate was coated with 1 µg/mL KJ1-26. DO11 (squares) and D10 (circles) scTCR 
were added in 3-fold dilution series and washed following 1 hour incubation.  Protein 
binding was detected with α-His HRP.  
 Based on principles derived for DO11 and D10, all subsequent scTCRs 
were oriented in this reverse arrangement, and the four described mutants were 
incorporated into TRBV13-2 containing constructs; the data in Table 3.1 reflects 
these design principles.  
 Later, when evaluating the binding of DO11 to its target antigen, we saw fit 
to examine the solubility-inducing mutants individually. Here we found that 
reversal of H54Y had no effect on soluble expression, while reversal of either 
G17E or the pair of I90T, L93S severely reduced expression (data not shown). 
However, we also find that the expression of DO11 conjugated to M13 pVIII in 
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phage display (described later) was extremely dependent upon a tyrosine at 
position 54. In the absence of this mutation, phage titers were extremely low 
(data not shown). It seems likely that the tyrosine at this position interacts 
favorably with fusion partners utilized in phage display and the yeast display 
library from which the mutant was originally isolated. 
 Despite the relative success of expression for scTCRs containing 
TRBV13-2, the presence of this gene alone is insufficient to ensure high-level 
expression, even when properly oriented and mutated. Of particular note, DO11 
production was particularly low (less than 5 mg/mL) when expressed from the 
pMoPac54 vector. pMopac54 is derived from pAK400, but creates a fusion from 
the c-terminus of the gene to the constant kappa region of light chain human 
IgG1 (161) In addition, expression was found to be very low in the vector 
pMoPac10 (161), which produces a protein identical to that of pAK400 (from 
which it was derived) save for the addition of a “myc” epitope tag at the c-
terminus (Kevin Entzminger, personal communication). Soluble DO11 expression 
was also very low in the previously described pAK500 vector (65), which fuses 
the c-terminus of the protein to a naturally dimerizing helix domain (data not 
shown). The sensitivity to c-terminal additions is also seen in the expression of 
some peptide fusions, described later. 
3.3.2.2. scTCR Grafts  
 Based on the high level expression of several scTCRs, we undertook two 
efforts to express pairs of TCRs as grafts. Grafting has been widely used as a 
technique for increasing the stability and expression of antibody fragments (164). 
Both of our efforts were ultimately abandoned due to poor expression of the 
resulting constructs. In the first case, we sought to use DO11 as a scaffold for the 
production of 2B4. TCR functionality is largely dictated by the interaction of six 
complementarity-determining regions, 3 per chain, with target peptide MHC. 
Since 2B4 is expressed at extremely low levels, we reasoned that we might 
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increase its expression by fusing its CDRs to the DO11 framework. DO11’s 
framework was left in tact save for these CDRs, as well as residues outside the 
designated CDR identified as important for preservation of canonical loop 
structures by Al-Lazikani et al (165). The expression of the resulting gene was no 
greater than 2B4 alone (data not shown). 
 Our second attempt at grafting was less ambitious. We sought to mix and 
match complementarity-determining regions of 172 and DO11 to enumerate the 
role of each region in recognition of peptide and MHC recognition. DO11 
recognizes ovalbumin 323-339 when presented by I-Ad. This peptide also binds 
with high affinity to 172’s cognate MHC, I-Au. DO11 and 172 are quite similar. 
They both incorporate TRBV13-2, meaning their CDR1β and CDR2β regions are 
identical. In terms of peptide/MHC recognition, therefore, the only differences lie 
in the respective CDR3s as well as CDR1α and CDR2α. Since CDR1 and CDR2 
mediate MHC recognition, while CDR3 is thought to impart peptide specificity. 
We therefore hypothesized that we could increase the affinity of DO11 for I-Au by 
replacing its CDR1α and CDR2α with those found in 172. We synthesized this 
construct and called it DO72 (Figure 3.5A). We also wondered whether we might 
impart specificity for I-Au in conjunction with OVA 323-339 to 172 by replacement 
of its CDR3α and CDR3β with those of DO11. We synthesized this construct and 
called it 17DO. It should be noted the prospects of 17DO seemed less attainable, 
given the propensity of peptides to occupy multiple conformations in I-Ad, and the 
unique orientation of 172 towards its cognate antigen ((166)).  
 Since we routinely express both DO11 and 172 at levels in excess of 30 
mg/L, the prospect of expressing high levels of the recombined variants of the 
two seemed feasible. Complementarity determining regions are by definition 
solvent exposed loops. In addition, the CDR1α and CDR2α loops that differ 
between the two TCRs share common predicted canonical conformations as 
predicted by Al-Lazikani et al (165). Nonetheless, expression of both 17DO and 
DO72 was significantly reduced as compared to their wild type counterparts. In 
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the case of DO72, soluble expression of the monomer was undetectable; for 
17DO, it was 3-5 fold reduced (Figure 3.5B).  
 
 
Figure 3.5. Grafts of 172 and DO11 scTCRs  
A, Composition of 17DO, in which CDR3α  and β  of 172 are replaced with the 
corresponding amino acids from DO11, and DO72, in which DO11 CDR1α  and CDR2α  are 
replaced with corresponding amino acids from 172. B, Shown are traces resulting from 
scTCRs purified from 100 mL of culture over an S200 size exclusion column. Expression 
of DO11 (solid line) is compared with the production of 17DO (dashes), and DO72 (square 
dots). 
3.3.2.3. Multimerization 
 To increase the avidity of our scTCRs and render binding to cognate 
pMHC more sensitive, we sought to create multivalent complexes. Tetramers can 
be simply created by the natural interaction of four biotins with avidin or one of its 
derivatives. To facilitate biotinylation of our scTCRs, we cloned two peptide 
sequences. The first, described as the most efficient substrate for the biotin 
ligase (167, 168) is referred to here as BSP1 (biotin ligase substrate peptide 1, 
Table 3.2). The second is commonly used tag also identified by Schatz et al., 
referred to here as the BSP2. In these tags, the lysine is specifically biotinylated 
by the enzyme. In addition to these enzymatic sites, we cloned a peptide 
selected for binding to streptavidin with nanomolar affinity, referred to here as 
BMP (Biotin mimic peptide, (169)).  
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Table 3.2. Peptide Tags for Tetramer Production 
 Addition of BSP1 to the N- terminus significantly increased expression of 
DO11, while C- terminal addition moderately decreased expression of the scTCR 
(Figure 3.6). N- terminal addition of BSP2 proved neutral for protein expression 
(data not shown). The addition of BMP at either terminus ameliorated expression 
of the protein monomer (Figure 3.7). This is likely due to the presence of cysteine 
residues utilized to create the shape of the tag that interacts with the streptavidin 
binding pocket, as additional cysteines often have the effect of inducing protein 
aggregation through misfolding. 
 
 
Figure 3.6. Expression of BSP1-linked DO11.   
Shown are traces resulting from scTCR fusions purified from 500 mL of culture over an 
S200 size exclusion column. Short peptide sequences were tethered to the n-terminus 
(solid lines) or c-terminus (dashed) of single chain DO11, both separated from the TCR on 
either terminus by a (GGS)2 linker.  
  75 
 
Figure 3.7. Expression of BMP-linked 172 and DO11.  
Shown are traces resulting from scTCR fusions purified from 100 mL of culture over an 
S200 size exclusion column. Streptavidin peptide was fused to the N- terminus (blue) or C-
terminus (black) of DO11, as well as the C- terminus of 172 (blue-dashed). 
 DO11 incorporating N- and C- terminal addition of BSP1 was enzymatically 
biotinylated using commercially available biotin ligase and free biotin. Excess 
biotin was dialyzed away, and proteins were evaluated for biotinylation efficiency 
using a western blot (Figure 3.8). Biotinylated DO11 was mixed with excess 
extravidin and run on an SDS-page gel, where DO11 bound to extravidin ran at 
significantly higher molecular weights. Protein was detected using α-His 
conjugated to HRP. Both N- and C- terminal DO11 showed biotinyation 
efficiencies only approximating 50%. The lower overall detection of C- terminal 
sequence 85 biotinylated DO11 in this blot is likely due to obstruction of the His 
tag. The formation of DO11 tetramers using biotinylated BSP1 also proved 
inefficient. Following gradual addition of extravidin, the complex was run on S200 
size exclusion column (Figure 3.9). The result appeared to be complexes of 
mostly TCR dimers in addition to the uncomplexed monomer resulting from 
unbiotinylated TCR. The low efficiency of biotinylation and subsequent tetramer 
formation may be due in part to inaccessibility of the sequence tags due to 
association with the scTCR. 
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Figure 3.8. Biotinylation Efficiency of BSP-tagged DO11. 
5.0 µg of biotinylated DO11 with the BSP1 biotinylation sequence N- (lanes 1,2) or C- (lanes 
5,6) terminally positioned was separated by a 4-20% gradient gel with (lanes 2,6) or 
without (lanes 1,5) the presence of equimolar and detected with α-His HRP. Extravidin 
alone was run in lane 4.  
 
Figure 3.9. DO11 Tetramers.  
N-terminally biotinylated DO11 was gradually mixed with extravidin to a 1:4 molar ratio 
and separated over S200 size exclusion column. Primary peaks from left to right 
correspond to dimer-extravidin, monomer extravidin, unconjugated T cell receptor, and 
buffer.  
 As an alternative to biotin-mediated tetramerization, we pursued 
dimerization via the use of an epitope tag. The amino acid sequence EYMPME 
(abbreviated EE) is a truncated version of the larger CEEEEYMPME epitope 
found in a polyoma virus antigen (170). A monoclonal antibody against this 
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antigen binds with relatively high affinity for an epitope tag, and the binding of a 
single antibody to two tag-containing scTCRs would present these in a dimerized 
form. We chose to place the EE tag at the N- terminus of the linker separating the 
beta and alpha chains (Figure 3.10). It was thought that locating the tag in the 
middle of the construct would minimize any obstruction associated with terminal 
placement. Insertion at the C- terminus of the beta chain rather than the N-
terminus of the alpha chain was chosen because of the previously observed 
insensitivity of TRBV13-2 to the addition of extra peptides. In addition to the 
addition of a single EE tag, we designed an insert with two tags in succession, 
separated by an additional Gly4Ser subunit. This was designed to maximize 
avidity of the tag towards its antibody, as linear epitope tags at times lack the 
affinity of other antibody-antigen interactions. Two proximal tags might increase 
rebinding of the antibody after dissociation, while their proximity to one another 
should preclude a single antibody from binding to both tags as a sterically 
unfavorable interaction. 
 
Figure 3.10. Insertion of “EE” Epitope Tags.   
Schematics on the right indicate location of EE tag insertion relative to alpha and beta 
variable region chains and Gly-Ser linker on the TCR. The accompanying chromatogram 
(left) shows relative production of each scTCR fusion purified from 250 mL of culture over 
an S200 size exclusion column for the EEv1 (dashed) and EEv2 variants.  
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 The insertion of both forms of the EE tag was well tolerated by DO11, and 
both were produced at high levels (>30 mg/L, Figure 3.10). The efficacy of this 
tag in producing functional dimers was evaluated using an ELISA. Plates were 
coated with KJ1-26. Dimers were assembled by gradual addition of monoclonal 
α−EE to a molar ration of 1:2, incubated, and detected by the addition of α-IgG1 
conjugated with HRP. Both versions of EE-tagged dimers were functional, with 
the EE-doublet showing slightly greater EC50 (Figure 3.11). 
 
Figure 3.11. Activity of EE-Tagged DO11 Dimers.  
ELISA wells were coated with 1 µg/mL KJ1-26. DO11 EEv1 (circles) and DO11 EEv2 
(squares) dimerized with 1:2 molar α-EE were added in 3-fold dilution series and washed 
following 1 hour incubation. Protein binding was detected with α-IgG1 HRP.   
3.3.2.4. IL10 Peptide Mimic 
 One potential use for scTCRs is as a targeting mechanism for specific 
peptide antigens displayed by the immune system. Interleukin 10 (IL-10) is a 
cytokine that is broadly anti-inflammatory, and can shift immune responses from 
a cell mediated inflammatory response to a humoral response (171) Given that 
overactive inflammatory response has been implicated in diseases such as 
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multiple sclerosis, psoriasis, rheumatoid arthritis, and inflammatory bowel 
disease, the use of IL10 as a therapeutic has been variously explored. Recently, 
a nonapeptide mimic with complete homology to the C- terminal portion of human 
IL10 has been shown to possess many of the functional properties of the 
complete cytokine (158-160). We decided to test the compatibility of this short 
peptide with our scTCRs. 
 The IT9302 peptide mimic (AYMTMKIRN) was cloned to express as a 
fusion protein in several ways. First, we directly linked to the N- terminus of DO11 
and 172. Second, we coded the sequence directly into pAK400 between the SfiI 
restriction site used for scTCR and the 6-His epitope tag. Expression was of both 
the N- terminal (Figure 3.12A) and C- terminal fusions (Figure 3.12B) were 
reduced compared to unmodified DO11 and 172 constructs. As an additional 
test, we created a version of the vector in which the peptide was expressed after 
the His Tag. Expression of this construct was increased relative to unmodified 
172 (Figure 3.12C). 
 
 
Figure 3.12. Fusion of IL10 Peptide Mimic. 
DO11 (solid lines) and 172 (dashed lines) were expressed with the IL10 peptide mimic 
IT9302 tethered to the scTCR by a (Gly2Ser)2 linker at the n-terminus (A) or c-terminus (B) 
prior to the His tag.  For 172, the peptide was also tethered after the His tag (C).  Each 
curve produced from S200 size exclusion chromatography of Ni2+isolated protein from 100 
mL of E. coli culture.  
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3.3.3. Phage Display 
 Given their relatively low affinities for target antigens, affinity maturation 
was pursued to increase the utility of scTCRs as reagents or therapeutics. Phage 
display was previously discussed as a means for affinity maturation (Section 
1.2.3). In the following section, we tested the applicability of current phage 
display systems for use with DO11 and 172. 
3.3.3.1. pIII Display of 172 
 Initially we tested the display of 172.10 in the pAK100 and pMoPac24 
display vectors that fuse the displayed protein to a truncated version of M13 
protein III (pIII). Particles were produced through induction of gene expression 
with IPTG and infection of “helper phage” containing complete viral genomes 
(65). Titres of approximately 1011 phage/ mL were produced and concentrated 
using 20% PEG-2.5M NaCl precipitation. Phage were resuspended in 50% 
glycerol in PBS and stored at -20° C.  
 Expression of scTCR on the particles was demonstrated via ELISA. Both 
pAK100 and pMoPac24 code for a “c-myc” amino acid tag between the protein 
and its fusion partner. Immobilized α−myc was used to pull down phage particles, 
which were then detected using α−pVIII, which binds to the major protein of the 
phage coat. The 172 scTCR showed similar levels of display to the control scFv 
14B7, as evidenced by a dose response to number of phage particles present 
(Figure 3.13A). 172 and 14B7 also produced similar phage titers (data not 
shown). 172 was more effectively displayed using the pMoPac24 vector, which 
coexpresses the skp chaperone protein (Figure 3.13B). 
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Figure 3.13. pIII Display of 172.  
172 scTCR was displayed as an M13 pIII fusion and panned against immobilized 1 mg/mL 
α-myc (A, B) or 0.4 µM MBP1-11 covalently linked to I-Au (C). Binding was detected by α-
pVIII HRP. 
 To demonstrate functionality of the displayed scTCR, particles were 
panned against immobilized MBP Ac1-11 covalently linked to I-Au. The interaction 
between MHC-peptide and TCR (Kd ~5 uM, (163)) is of lower affinity than that of 
the antibody/tag, yet we still observe dose-dependent interaction (Figure 3.13C). 
3.3.3.2. Protein VIII Display 
 For some lower affinity scTCRs, display on pIII may be insufficient to allow 
for target binding, given the absence of any avidity effect. pVIII, on the other 
hand, comprises the bulk of the phage coat, and on the order of 1000 copies are 
present per phage. Based on this successful display of 172 in pMoPac24, we 
opted to modify this vector to fuse incorporated proteins to full-length pVIII. 
 Despite high copy numbers of pVIII present on each phage particle, 
previous efforts at displaying larger fusion proteins has produced mixed results 
(172, 173). This difficulty is likely due to the close-packed nature of this protein, 
and the necessary close association of a displayed protein with its fusion partner. 
To improve display via pVIII, Sidhu et al. constructed five libraries of protein VIII 
variants and selected for the display of human growth hormone (174). Each 
library consisted of random mutants spanning ten amino acids, one for each of 
  82 
the five segments of this 50 amino acid protein. From these, he selected several 
optimized variants for each of the first three n-terminal most segments. In a 
separate publication (175), the utility of each individual mutation was evaluated. 
Given the possibility that the increased display demonstrated by these mutants 
was based proximity to and specific interactions with the HGH used in selection, 
we opted to synthesize all three of the described pVIII variants and test their 
efficacy in the display of DO11 (Table 3.3). 
 
 
Table 3.3. Variants of pVIII for phage display.  
Three variants were cloned into pMoPac24 for fusion based phage display based on the 
work of Sidhu et al. (174). Mutations in each variant were limited to a single 10 amino acid 
segment.  
 Wild-type protein VIII and the three optimized variants were synthesized 
via PCR amplification of oligonucleotides with flanking Asc I and Hind III 
restriction sites. These fragments were ligated into pMoPac24 in place of the pIII 
fusion to produce pMo24p8, pMo24p8o1, pMo24p8o1, and pMo24p8o3. We then 
cloned DO11 and control scFv 14B7 were cloned into each of the variants and 
assessed for display of the fusion protein. 
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 Vectors were transformed into XL1-B, and phage particles were produced 
by infection of M13KO7 and concurrent induction with IPTG, followed by 
expression for up to 24 hours. Phage titers were evaluated as colony forming 
units, and varied greatly among the variants. For 14B7, the pVIIIo1 fusion 
produced the highest titers, followed by pVIIIo2 and pVIII WT, with pVIIIo3 
showing very low levels of production. For DO11, on the other hand, titers of the 
wild type and pVIIIo2 were roughly equal, with significantly lower titers shown for 
pVIIIo1 and pVIIIo3. As a whole, titers ranged from nearly equal magnitude to pIII 
display to over four orders of magnitude lower Figure (3.14). 
 
Figure 3.14. pVIII-associated phage titers are specific to the displayed protein. 
 Next, particles were evaluated for the display of the fusion protein (Figure 
3.15). Phage was panned against immobilized binding target, KJ1-26 for the 
case of DO11, and anthrax protective antigen (PA) for 14B7. Binding was 
detected by α-pVIII HRP. Both proteins showed slightly lower display via pVIIIo1 
when compared to the wild type fusion. For DO11, both pVIIIo2 and pVIIIo3 
showed significantly improved display; for 14B7, pVIIIo2 display was similar to 
that of the wild type, while pVIIIo3 titers were too low to judge. 
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Figure 3.15. pVIII Display of DO11 and 14B7.  
DO11 scTCR (A) and 14B7 scFv (B) were was displayed as on M13 fused to pVIII (circles) 
or an optimized variant and panned against immobilized 1 µg/mL KJ1-26 or anthrax 
protective antigen. Binding was detected by α-pVIII HRP.  
 To compare the effective avidity of pVIII and pIII display, phage particles 
were used to block the interaction of DO11 cells with A20 antigen- presenting 
cells (Figure 3.16). Phage particles were added to 96-well plates in a dose-
dependent manner. Stimulatory peptide (20 µM) was added to 15,000 A20 
lymphoma B cells presenting I-Ad and 15,000 DO11 Hybridoma cells, and 
allowed to incubate for 24 hours. Phage displayed variants pVIIIo2 and pVIIIo3 
were found to inhibit the production of interleukin 2 by DO11 cells at titers of 
approximately two orders of magnitude lower concentration than pIII displayed 
phage. Particles displaying pIII, on the other hand, were similar in efficacy of IL2 
inhibition to M13 phage particles alone. 
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Figure 3.16. Inhibition of IL2 Release by pVIII-displayed DO11.  
Phage particles alone (diamonds) or displaying DO11 scTCR on pIII (circles), or pVIII 
variants o2 (squares) or o3 (inverted triangles) were incubated in the presence 20 µM 323-
339 peptide along with 15,000 DO11 T cell hybridoma cells and 15,000 A20 B Cell 
lymphoma cells. Release of IL2 into the supernatant was quantified by matched pair 
ELISA.  
3.3.4. Affinity Maturation of DO11. 
3.3.4.1. Selection of Phage Display System 
 The first step in the maturation of DO11 was in choosing an antigen to pan 
against. Typically, an isolated peptide covalently linked to an MHC would be 
appropriate, covalently linked ova 323-339 I-Ad has proven ineffective at staining 
DO11 T hybridoma cells, for reasons discussed in Chapter 2. As a result, 
maturation against the α−idiotype antibody KJ1-26 was used. Due to the higher 
affinity of this interaction relative to the native TCR-pMHC, pIII-based display was 
first attempted. 
 As a demonstration of the feasibility we initially showed enrichment of 
particles with DO11 displayed from severe dilution within 172-displayed particles. 
DO11 particles were diluted at a rate of 1:1000 or 1:1000 with pIII-displayed 172 
(Figure 3.17). The combined mix of particles was panned against KJ1-26 or a 
non-specific antibody, eluted with a solution of low pH glycine, neutralized with a 
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high pH Tris buffer, reinfected into ER2738 cells and amplified overnight prior to 
another round of panning. For DO11 phage alone, between 104 and 105 colony 
forming units were eluted per between 109 and 1011 cfu inputted to each round of 
panning. For DO11 diluted one to a million in 172 phage, on the order of 100 
particles were selected after a single round of panning, increasing to 10,000 after 
four successive rounds of selection and amplification, indicating that pIII 
displayed DO11 is effectively selected for in panning against KJ1-26. 
 
 
Figure 3.17. Enrichment of DO11 Phage Panned Against KJ1-26. 
DO11 scTCR displayed as a pIII fusion alone (A) or diluted 1:1,000 (B) or 1:1,000,000 (C) in 
pIII- displayed 172 particles was panned against immobilized KJ1-26 (1 µg/mL). Black 
columns show total phage inputted to each round of panning, gray columns show total 
phage eluted from following KJ1-26 binding and white columns show total phage eluted 
from wells coated with control antibody. 
3.3.4.2. Selection of Affinity Matured Mutants.  
 Site directed mutagenesis was used to randomize the CDR3α region of 
DO11. Prior to randomization, three consecutive “stop” codons were initially 
introduced into the wild type DO11 using full amplification of the vector. These 
stop codons prevent wild type DO11 from outcompeting variants, as each 
individual variant is present in low quantities prior to any selection. Single 
stranded DNA was then isolated from phage carrying the stop codon-laden DO11 
template. Libraries were created by the slow annealing of oligonucleotides 
containing random codons to this template followed by extension of the primer 
around the plasmid at room temperature and ligation. Libraries were then 
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transformed via electroporation into XL1B cells. Cells were then infected with 
helper phage, induced to express protein with 1 mM IPTG and grown overnight 
to produce phage libraries. 
 Two separate libraries were created, each introducing six random codons 
into CDR3α. The first preserved the 10 amino acid length of the wild type CDR, 
randomizing from position 107 through 115 (standard IMGT numbering includes 
amino acids not present in some TCRs, Table 3.4), preserving the reasonably 
well conserved alanine at position 106 and leucine at 116. The second library 
randomized positions 106 and 116, but created a shorter overall CDR3α of 8 
amino acids. “NNS” codons were used for randomization, where N can be any or 
the four possible nucleotide bases and S is restricted to guanine or cytosine, to 
limit the number of stop codons within the library. Each library contained 
approximately 106 variants and was panned in five successive rounds against 
immobilized KJ1-26. 
 During the course of panning, the 8 amino acid- length library was 
eventually overtaken by contaminating variants from the 10 amino acid-length 
library, likely indicating a lower inherent affinity in the shorter library. Both 
libraries were also contaminated by wild type DO11, which was unable to 
outcompete several members of the 10 amino acid library. Selected DO11 
variants are presented in Table 3.4. 
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Table 3.4. Selected Variants from DO11 CDR3α  Library.  
Gray residues were unmodified by random codons. Positional numbering is according to 
IMGT. Bolded variants were cloned into pAK400 for further analysis  
 Three mutants were chosen to for further comparison to DO11. Each was 
subcloned into pAK400, expressed, and purified from BL21 cell culture. Yields 
were comparable to DO11 (data not shown). Each was then tested in ELISA 
against KJ1-26, with detection by α-His HRP, with two of the three mutants 
showed significantly higher EC50 (Figure 3.18).  
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Figure 3.18. Activity of Affinity-Matured DO11 Variants.  
Affinity matured variants of DO11 were cloned into pAK400 and expressed as soluble 
proteins. Following purification, protein doses were incubated with immobilized KJ1-26 
coated at 1 µg/mL in 96 well plates. Binding of DO11 (circles) 235 (inverted triangles) 174 
(triangles) and 176 (squares) was detected with α-His HRP. Diamonds indicate the average 
of all samples bound to an irrelevant protein.  
 Variants 176 and 235 were further measured for affinity against KJ1-26 
with BIACore. KJ1-26 was immobilized and monomer DO11 and variants were 
flowed across the surface with the antibody, while changes in resonance were 
monitored for the determination of on- and off-rates. These results paralleled the 
capture ELISA, with 176 showing approximately two orders of magnitude higher 
affinity than DO11 (Table 3.5). The increase in affinity was primarily due to 
slower off rate (Figure 3.19). Variant 235 showed approximately equal affinity to 
DO11. 
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Figure 3.19. Determination of DO11 Variant Affinity with BIACore.   
Purified DO11 scTCR and variants were assessed for affinity to KJ1-26 with BIACore 2000. 
Shown are representative curves of 176 (pink), 235 (brown), and DO11 (red) at 200nM 
flowed at 35 µL/min over 600 RU KJ1-26 immobilized to chip. 
 
Table 3.5. Affinity of DO11 Variants. 
Kinetic data were fitted for association and dissocation rate constants from duplicate, 
two-fold dose response sereies descending from 400 nM using BIAEvaluation software. 
 Based on the higher affinity of 176 against KJ1-26, this variant was tested 
for its ability to stain A20 antigen-presenting cells. Two consecutive EE tags were 
inserted prior to the linker, as described in Section 3.3.2.3, and the protein was 
expressed in BL21 cells. Dimers were formed from purified monomer by the 
stepwise addition of monoclonal α−EE to a 1:2 molar ratio of antibody to scTCR. 
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Fluorescent tetramers were further formed from dimers by the gradual addition of 
allophycocyanin (APC)-conjugated monoclonal α-IgG1 (Figure 3.20).  
 
Figure 3.20. Representation of Assembled, EE Tag-based Tetramers. 
 A20 cells (250,000) were then incubated with 50 µM peptide along with 
0.5 µg DO11 or 176 in tetramer form. EE-tagged, tetramerized maltose binding 
protein was used in equimolar amounts as a control. Results indicate that 176 
stains cells more efficiently than DO11 (Figure 3.21B). Somewhat surprisingly, 
given the antibody substitute used for affinity maturation, 176 also exhibits 
peptide specificity (Figure 3.21C) in staining APCs, which is not seen for DO11 
(data not shown). 
  92 
 
Figure 3.21. Fluorescent Staining of A20 Cells with DO11 and 176. 
Purified scTCR (0.5 mg) or equimolar EE-tagged Maltose binding protein bound to α-EE 
and α-IgG1 was used to stain A20 lymphoma cells in the presence of 50 mM ova 323-339 
peptide. A: DO11 (black) is compared with unstained control (gray) and maltose binding 
protein (gray, filled). B: 176 (black) is compared with DO11 (gray, filled). C: 176 is shown 
with (black) and without (gray, filled) the addition of ova peptide.  
3.4. Discussion 
3.4.1. scTCR Expression 
 The observed stability of TRBV13-2 containing scTCRs seems not to be 
unique among variable regions, as a similar effect has been demonstrated for the 
human TRAV-12 family (176). Neither, it should be noted, is it universal, as 
solubility-inducing mutations and chain order are important, and various peptide 
tags significantly decreased expression.  
 The preference for “β-first” scTCR orientation could result from one of 
several effects. In the case where alpha and beta chains exhibit significantly 
different thermodynamic stabilities, the beta chain may drive proper folding of the 
less stable alpha chain. Stable bacterial proteins such maltose binding protein 
are commonly fused with difficult to express partners with great success. It may 
be that when the beta chain is translated first, it can fold rapidly and provide 
assistance for it’s alpha binding partner during folding. A more likely explanation, 
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in our opinion, can be gleaned from data gathered in our various scTCR fusion 
constructs. In the standard construct expressed by pAK400, the n-terminus of the 
initially expressed variable region (α or β) is fused to a pelB leader sequence, 
which aids in transport of the protein to the periplasm. Likewise, the C- terminus 
is fused to a linker plus the N- terminus of the subsequent chain. Given that we 
observe that α chain of DO11 is relatively intolerant to peptide or fusion protein 
additions at its at C- terminus, that preference probably applies for effective 
"linker-β” C- terminal tag necessitated by the forward conformation. Likewise, the 
β chain tolerance for N- terminal fusions likely carries over to its tolerance of the 
pelB leader sequence. 
 The lack of expression of attempted grafts of DO11 (with 2B4 and 172) 
could be further explored using DNA shuffling or random mutagenesis for insight 
into previously unidentified amino acid positions important in genetically encoded 
CDR1 and CDR2 presentation. Notably, the greater expression of 17DO as 
compared to DO72 (Figure 3.5B) is perhaps reflective of the inherent tolerance of 
TCRs towards various CDR3 compositions.  
3.4.2. Affinity Maturation 
 The selected variants from the DO11 library showed moderate 
conservation at for four of the six randomized codons: 107S, 109N, and 113Y 
(Table 3.5). Of the seven selected variants from the 10 amino acid-length library, 
at least 3 incorporate a wild-type residue at these positions. A non-native 
histidine at position 114 was selected in four of the seven unique variants. 
Further recombination of the selected mutants may yield greater affinity 
enhancement. 
 To our knowledge, the variant 176 marks the only the second reported 
affinity variant of TCR to a Class II peptide MHC. The use of KJ1-26 as a binding 
partner facilitated the panning, but it is unclear whether other anti-idiotypes would 
be similarly well suited to serve as proxies for native binding target. Given the 
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differences in the native structure of antibodies and peptide-MHC constructs, it is 
difficult to imagine the former mimicking the latter with any notable frequency. It 
is possible, however, that using a small scTCR for mouse immunization or 
panning against a naïve library would yield such variants with greater frequency. 
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CHAPTER 4 
 PRIMER SET FOR THE AMPLIFICATION OF MOUSE TCR CDNA  
4.1. Introduction 
 The description and characterization of a primer set is shown here for the 
amplification of murine cDNA for use in the high throughput sequencing of the 
TCR repertoire. Sequencing with the next generation 454 pyrosequencing-based 
technology is currently being performed with the goal of evaluating changes in 
TCR usage associated with ovalbumin immunization. The resulting data is being 
processed, so the current description is limited to a feasibility study in which 
TCRs were identified from two previously described “Type B” cell lines followed 
by a small-scale preliminary 454 sequencing run. 
 High throughput sequencing has the potential to delineate the relationship 
between T cell receptor sequence and the function of host T cells. Receptors 
have been suspected of influencing T cell development towards specific subsets 
based on their inherent binding affinities; high affinity receptors are thought to 
play a role in the development of regulatory cells (17, 19) and memory cells 
(177). Recent deep sequencing work in humans, however, has suggested that T 
cell differentiation is stochastic, as identical receptors are found throughout 
various subsets (178). In addition, the preferential usage of certain genes has 
long been noted in the certain immune responses, for instance, usage of 
TRBV13 in murine models of autoimmune disease (179). Deep sequencing of 
selected subsets has the potential to resolve these long-held observations as 
well as to provide a wealth of information about the development of various 
disease states. 
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4.2. Materials and Methods 
4.2.1. Primer Set Design 
 Oligonucleotides were designed for the amplification of mouse TCR α and 
β cDNA based on reference sequences of each gene and listed allele from IMGT 
(180). The constant region of each chain was targeted with a single α-sense 
oligonucleotide (α: 5’- GTGCTGTCCTGAGACCGAGG- 3’; β: 5’- 
GCCTTTTGTTTGTTTGCAATCTCTGC- 3’), which anneal 12 residues into each 
constant region. Individual sense strand primers were designed to be 
complementary to catalogued leader sequences (Table 4.1, 4.2) according to 
principles described below. Primers recognizing pseudogenes (gene fragments 
with stop codons or frameshifts such that an in tact TCR is not produced) were 
not included were omitted from consideration in design as not relevant to the in 
vivo repertoire. Genes from the additional duplication event seen in C57/BL6 
mice (marked “N” by IMGT) were also omitted from consideration, as were delta 
genes not shared with the alpha repertoire. (Figure 4.1) 
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Figure 4.1. Mouse TCRα  Locus  
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A representation of the mouse TCRa locus from chromosome 14. Green indicates a 
functional gene, yellow an open reading frame, and red a pseudogene. Genes denoted 
with an “N” appear only in mice of the C57/BL6 strain. (Source: (180))  
4.2.2. 4C4 and 3B6 
 Two murine T cell lines, 4C4 and 3B6 reactive to a human myelin basic 
protein peptide were obtained from Thomas Forsthuber (University of Texas-San 
Antonio) for the purpose of extracting TCR Sequences. 
4.2.3. Immunization and Cell Sorting 
 Four 25-27 week old BALB/c mice were each immunized with 100 µg of 
ovalbumin or PBS in CFA in two subcutaneous injections behind the shoulder 
blades. After 14 days, spleens and lymph nodes were harvested. Lymph nodes 
were immediately transferred to RNA later (Invitrogen) and stored at -80 C prior 
to total RNA isolation. Splenic tissue was disrupted with the plunger of a syringe 
and passed through a cell strainer for subsequent isolation of T cell subsets. 
Following red blood cell lysis, cells were separated by first isolating CD4+, then 
CD8+ cells using magnetic Dynabeads (Invitrogen #114.45D, 114.47D) by 
incubation for 20 minutes at 4 °C with gentle rotation. Beads were magnetically 
separated from supernatant and stored in TRIzol reagent (Ambion). 
4.2.4. TCR Amplification 
 Total RNA was first purified from isolated cell populations. Cells were 
lysed in TRIzol (Ambion) through homogenization (OMNI GLH), repeated 
drawing through 23-gauge needle and syringe, or extensive vortexing (for bead-
bound populations). Following the addition of 1- bromo 3- chloropropane and 
centrifugation, RNA was isolated from the aqueous phase. RNA was further 
purified through by ethanol precipitation on a column using QIAgen’s RNEasy kit. 
DNA contamination in purified samples was degraded using DNA-free treatment 
kit (Ambion). Samples were stored  
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 cDNA was obtained through reverse transcription using SuperScript RT II 
(Invitrogen) extension of oligo(dT) primers for 50 minutes at 42 °C. T cell 
receptors were amplified from cDNA through amplification of with 25-30 cycles of 
PCR using the primer set and Accuprime pfx polymerase (Invitrogen). Resulting 
DNA was separated on a 1.5% agarose gel and purified using QIAgen’s 
QIAquick gel extraction kit. Purified DNA was cloned into Zero Blunt TOPO kit or 
submitted to the Genome Sequencing and Analysis Facility at the University of 
Texas for adaptor ligation and subsequent high throughput sequencing using a 
Roche/454 FLX Titanium Series Instrument. 
4.2.5. Data Analysis 
 Preliminary high throughput sequencing data was submitted to VQuest at 
IMGT.org (181) using a script developed by Zach Frye (The University of Texas 
at Austin).  
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4.3. Results and Discussion 
4.3.1. Primer Set Design and Validation 
 Several principles guided the design of TCR primers. A minimum number 
of overall primers were desired. Degeneracy was introduced into primers based 
on available sequence data when necessary, but limited to four or fewer 
“versions” of each primer (e.g. related primers in which one position is allowed to 
randomize to all four possible nucleotides). In order minimize the number of 
primers as well as the degree of degeneracy, the length of each primer was 
selected such that the melting temperature of each primer was approximately 55 
°C. Primers were annealed to leader sequences with the exception of TRBV13, 
which targeted a conserved region at the beginning of the framework.  
 
Table 4.1. Primers used in the amplification of TCRα  genes 
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 For TRAV, a total 28 primers were designed (excluding multiples of 
degenerate versions) to target 82 genes. The mouse alpha region features a 
duplication event (and a triplication event in the C57/BL6 strain), and genes are 
grouped according to families (Figure 4.1, (182)). Several families contained 
diversity necessitating multiple primers for amplification of a single family. The 
average melting temp was 55 °C, ranging from 52-59 °C. For TRBV, 19 primers 
were designed to amplify 22 genes. Average melting temp was 56 °C with a 
range of 54-57 °C.  
 
Table 4.2. Primers used in the amplification of TCRβ  genes  
 In the potential case that high throughput sequencing reveals previously 
unobserved variable region alleles, the designed primer set may require 
additional members. However, the low Tm of the set is expected to allow for 
some mispairing. In addition, a relatively high degree of conservation is seen 
among known leader sequences. In cases where we have targeted a single gene 
with a degenerate primer from the set, no bias toward a particular conformation 
of that primer was detected (data not shown). 
 Primers were validated by amplification of murine cDNA. Lymph nodes 
were isolated from unimmunized mice, and individual reactions for each primer 
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were used to amplify α (Figure 4.2) and β (Figure 4.3) TCR genes. Amplification 
of genes was observed for each primer, with the exception of TRBV23. This gene 
has been previously noted as non-functional due to the absence of a splice donor 
site required for removal of the leader exon (183). Although proper-length 
transcripts have been identified for this gene, these may be the result of 
chromosomal rearrangement with a sister chromosome (184). Random individual 
bands from α and β were cloned into a topoisomerase cloning vector and 
sequenced to confirm the presence of at least one targeted gene amplified by 
each primer. 
 
Figure 4.2. TRAV Primer Validation.  
TCRα  variable region fragments were amplified from cDNA of lymph node origin from 
unimmunized mice by individual primers from the primer set. 
 
Figure 4.3. TRBV Primer Validation.  
TCRβ  variable region fragments were amplified from cDNA of lymph node origin from 
unimmunized mice by individual primers from the primer set. 
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4.3.2. Type B T Cell Receptor Isolation 
 As an initial feasibility study, we aimed to identify the TCR genes 
expreseed by several “Type B” T cell lines. These two lines are reactive to 
human myelin basic protein fragment 82-100 presented by HLA-DRB5*0101 
were previously isolated from transgenic mice expressing this human MHC gene 
(185). The number of unique T cells within each line was previously unknown. 
First, total RNA was isolated from approximately ten million cells and amplified 
using the TCR primer set. Gel-purified PCR product was Topo-cloned and 
sequenced, to reveal a single functional α and β gene for the 4C4 line, using 
segments TRAV7D-2, TRAJ5; TRBV4, TRBD1 and TRBJ2-7. 
 For the 3B6 line, a single α gene using the TRAV7D-2 and TRAJ2 
segments was recovered along with two functional β genes using the TRBV17, 
TRBD1, TRBJ1-1; TRBV20, TRBD1 and TRBJ1-4 segments and an additional 
non-functional gene using TRBV5, TRBD1 and TRBJ1-2. The results of the PCR 
amplification using individual β primers and 3B6 mRNA is shown in Figure 4.4. A 
splicing variant of the TRBV20 gene including the Cβ0 alternate cassette exon 
was also found, with an additional 24 amino acids inserted between the constant 
and variable domains. This variant has been previously demonstrated as 
functional as protein and occurring frequently in TRBJ1-containing receptors 
(186). The presence of three β genes implies the existence of at least one 
additional alpha gene for 3B6, but no others were recovered from traditional 
Sanger sequencing of Topo-cloned PCR products. 
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Figure 4.4. Amplification of 3B6 β  genes.  
cDNA from a “Type B” T cell line was amplified from using individual primers from the 
TCRβ  set. One non-function and two functional rearranged genes were identified.  
4.3.3. High Throughput Sequencing 
 A large-scale, high throughput sequencing project was designed using the 
primer set to analyze usage patterns in ovalbumin immunized versus control 
mice. CD4+ and CD8+ were separated from mouse splenocytes fourteen days 
after injection for two ova-immunized mice as well as two controls. Sequences 
were separated by mouse identity as well as T cell type. As of this writing, over 
460,000 raw sequences had been generated at an average of around 320 bp in 
length with a mode of 420 bp. Analysis of this data is currently in progress.  
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Figure 4.5. Mouse CD8 TCRs for 454 Sequencing.  
TCRs were amplified from the cDNA of CD8 isolated from splenocytes of an OVA- 
immunized mouse, separated on a 1.5% agarose gel (shown), purified, and bar-coded for 
454 high-throughput sequencing. Left:TCRα , Middle: Ladder, Right,: TCRβ . The lower 
band in β  is a result of the framework-targeting TRBV13 primer  
 A small-scale, preliminary trial was performed prior to this larger run. Here, 
4,882 sequences were obtained from splenic CD4+ TCR cDNA amplified from a 
single, ovalbumin immunized mouse. Samples were first processed through 
IMGT’s Vquest to remove non-TCR sequences, then filtered using crude cut-offs 
for length and sequence quality. Within the remaining 3,922 transcripts, Fifty-five 
of the 82 targeted genes were present, with notably high levels of diverse, 
functional transcripts from the TRAV7, 12, and 13 families (data not shown). 
 Germline segments not represented in the sequencing data were: TRAV1, 
TRAV2, TRAV5-1, TRAV5X-4, TRAV6x-6, TRAV8X-1, TRAV8X-2, TRAV10X, 
TRAV16X, TRAV17, TRAV18, TRAV19, and TRAV21. The TRAV 5X-4 primer 
sequence has previously been demonstrated to be functional in TCR 
amplification from a hybridoma (data not shown). Two other of primers may be 
targeting non-functional alleles. Variable region 18 (TRAV18) was targeted 
despite its one recorded allele being noted as an open reading frame (Figure ). 
Likewise, the first recorded allele of variable region 19 is an open reading frame, 
and the second contains a stop codon, whereas a third reported allele was 
functional. Pseudogenes have also been recorded for alleles in both of the genes 
(TRAV10, TRAV10D) targeted by the TRAV10 primer. 
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 Usage of TCR germline segments in the α region has historically been 
difficult to judge because of the sheer number of genes involved, and the lack of 
specific antibodies. The 13 primers that did not amplify TCRs in our preliminary 
sequencing experiment target a total of 17 genes. This is much lower than the 
average for our 28 member primer set, which targets a total of 82 unique genes. 
It is possible that these are infrequently used genes that have, as a result, not 
been selected for in the mouse like the larger-member families. This trend will be 
explored when a larger data set utilizing more refined filters becomes available.  
  The preliminary sequencing also revealed a possible error in the IMGT 
database, as TRAJ47 showed a conserved phenylalanine at position 117, rather 
than the denoted cysteine, and was observed in multiple functional transcripts. 
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CHAPTER 5 
FUTURE DIRECTIONS 
 The various topics combined in this work may be synthesized in future 
research to yield a clearer picture of epitope presentation in health, disease, or 
vaccination. Several applications seem feasible. In the case of high-throughput 
sequencing, OVA 323-339 reactive subsets should be isolated prior to 
sequencing with newly- developed pMHC tetramers (97) designed to restrict 
binding of the peptide to the register of interest. By itself, the pre-screening step 
would yield insight into the nature of the TCR-based response to the antigen. The 
development of TCR-based reagents from sequenced receptors, however, 
requires additional information about chain pairing. A potential solution could be 
attempted based on the protein expression results observed here. Given the 
stability of TRBV13-2, clones from the sequence results containing this chain, or 
DO11β itself, might be used as a scaffold for pairing with frequently occurring α -
chains from the sequence results. TRBV13-2 plus “high transcript-level α"- 
scTCRs could be grown in E. coli 96-well plates for rapid screening of tetramer or 
KJ1-26 binding. Used as a general platform, this method could effectively filter 
the process of identifying TCRs of interest, while simultaneously increasing the 
chances that these TCRs will be amenable to engineering in the robust bacterial 
host. 
 From a broader perspective, the power of display technologies has yet to 
be tapped for the engineering of T cell receptors. TRBV13-2 displays a degree of 
generality in expression when paired with various alpha chains, but remains the 
exception in this regard. Importantly, solubility-increasing amino acid 
substitutions identified for the 2C TCR (187) have the same effect when 
introduced onto many other Vβ chains, demonstrating that these protein can 
exhibit some generality. More work needs be done in exploring the structural 
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requirements for soluble expression. So that these can substitutions can be 
predicted a prior for additional TCR genes, without requiring directed evolution or 
crystallization experiments. DNA shuffling of related TCRs with wide ranges of 
bacterial expression levels could yield insight into important residues in solubility 
and stability in these molecules. Simple selection with a c-terminal epitope tag in 
phage display could be used in screening for expression. 
 Regarding the affinity-matured 176 variant, we are interested in the limits 
of KJ1-26 as a pMHC mimic. At some point, affinity with the antibody would likely 
fail to translate to the cognate antigen. A first step would be the investigation of 
the variant 174, which showed increased KJ1-26 binding as a soluble protein. 
Recombination of substitutions observed in 235, 176 and 174 would likely 
produce an “improved” variant, given the small coverage of six possible 
randomized codons that a 106-member library provides. CDR2β randomization of 
DO11 would also provide an interesting test case, given that others have shown 
that randomization of this MHC-targeted region can provide peptide specificity 
(149). 
 The 176 variant itself is also in need of further investigation. The peptide 
showed peptide specificity to OVA 323-339 in flow cytometry, but this could 
conceivably be due to the conformation of MHC induced by the presence of that 
peptide, which is commonly observed as differential mobility in an SDS-PAGE 
gel. Early experiments with maturation make it clear that cross-reactivity is a 
concern when targeting peptide specificity (188). Testing for cross-reactivity the 
QAV13-25 hen egg lysozyme variant peptide, in particular, would be of interest, 
given the evidence presented in Chapter 2 suggesting that this peptide binds to 
the MHC in similar fashion to OVA at the N-terminus.  
 Last, another potentially significant finding reported here is that flanking 
residues can increase peptide presentation. If this holds for other peptides, it may 
allow for engineering of peptides in vaccines in positions that don’t affect T cell 
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interaction. This could be impactful, given that typical anchor residue substitution 
techniques can significantly impact T cell response. 
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